Combined oral contraceptive pill

"The pill" redirects here. For other uses, see Pill (disambiguation).

This article is about daily use of COC. For occasional use, see Emergency contraception.

The combined oral contraceptive pill (COCP), often referred to as the birth control pill or colloquially as "the pill", is a type of birth control that is designed to be taken orally by women. The pill contains two important hormones: a progestin (a synthetic form of the hormone progestogen/progesterone) and estrogen (usually ethinylestradiol or 17β estradiol).^[9][10][11] When taken correctly, it alters the menstrual cycle to eliminate ovulation and prevent pregnancy.

Combined oral contraceptive pill
Background
Type	Hormonal
First use	1960 (United States)
Failure rates (first year)
Perfect use	0.3%^[1]
Typical use	9%^[1]
Usage
Duration effect	1–4 days
Reversibility	Yes
User reminders	Taken within same 24-hour window each day
Clinic review	6 months
Advantages and disadvantages
STI protection	No
Periods	Regulated, and often lighter and less painful
Weight	No proven effect
Benefits	Evidence for reduced mortality risk and reduced death rates in all cancers.^[2] Possible reduced ovarian and endometrial cancer risks.^[3]^[citation needed]^[citation needed] May treat acne, PCOS, PMDD, endometriosis^[citation needed]
Risks	Possible small increase in some cancers.^[4]^[5] Small reversible increase in DVTs; stroke,^[6] cardiovascular disease^[7]
Medical notes
Affected by the antibiotic rifampicin,^[8] the herb Hypericum (St. Johns Wort) and some anti-epileptics, also vomiting or diarrhea. Caution if history of migraines.

COCPs were first approved for contraceptive use in the United States in 1960, and remain a very popular form of birth control. They are used by more than 100 million women worldwide ^[12][13] and by about 9 million women in the United States.^[14][15] From 2015 to 2017, 12.6% of women aged 15–49 in the US reported using COCPs, making it the second most common method of contraception in this age range (female sterilization is the most common method).^[16] Use of COCPs, however, varies widely by country,^[17] age, education, and marital status. For example, one third of women aged 16–49 in the United Kingdom currently use either the combined pill or progestogen-only pill (POP),^[18][19] compared with less than 3% of women in Japan (as of 1950–2014).^[20]

Combined oral contraceptives are on the World Health Organization's List of Essential Medicines.^[21] The pill was a catalyst for the sexual revolution.^[22]

Mechanism of action

Combined oral contraceptive pills were developed to prevent ovulation by suppressing the release of gonadotropins. Combined hormonal contraceptives, including COCPs, inhibit follicular development and prevent ovulation as a primary mechanism of action.^{[23][24][25][26]}

Under normal circumstances, luteinizing hormone (LH) stimulates the theca cells of the ovarian follicle to produce androstenedione. The granulosa cells of the ovarian follicle then convert this androstenedione to estradiol. This conversion process is catalyzed by aromatase, an enzyme produced as a result of follicle-stimulating hormone (FSH) stimulation.^[27] In individuals using oral contraceptives, progestogen negative feedback decreases the pulse frequency of gonadotropin-releasing hormone (GnRH) release by the hypothalamus, which decreases the secretion of FSH and greatly decreases the secretion of LH by the anterior pituitary. Decreased levels of FSH inhibit follicular development, preventing an increase in estradiol levels. Progestogen negative feedback and the lack of estrogen positive feedback on LH secretion prevent a mid-cycle LH surge. Inhibition of follicular development and the absence of an LH surge prevent ovulation.^[23][24][25]

Estrogen was originally included in oral contraceptives for better cycle control (to stabilize the endometrium and thereby reduce the incidence of breakthrough bleeding), but was also found to inhibit follicular development and help prevent ovulation. Estrogen negative feedback on the anterior pituitary greatly decreases the secretion of FSH, which inhibits follicular development and helps prevent ovulation.^[23][24][25]

Another primary mechanism of action of all progestogen-containing contraceptives is inhibition of sperm penetration through the cervix into the upper genital tract (uterus and fallopian tubes) by decreasing the water content and increasing the viscosity of the cervical mucus.^[23]

The estrogen and progestogen in COCPs have other effects on the reproductive system, but these have not been shown to contribute to their contraceptive efficacy:^[23]

• Slowing tubal motility and ova transport, which may interfere with fertilization.
• Endometrial atrophy and alteration of metalloproteinase content, which may impede sperm motility and viability, or theoretically inhibit implantation.
• Endometrial edema, which may affect implantation.

Insufficient evidence exists on whether changes in the endometrium could actually prevent implantation. The primary mechanisms of action are so effective that the possibility of fertilization during COCP use is very small. Since pregnancy occurs despite endometrial changes when the primary mechanisms of action fail, endometrial changes are unlikely to play a significant role, if any, in the observed effectiveness of COCPs.^[23]

Formulations

Main article: Oral contraceptive formulations

Oral contraceptives come in a variety of formulations, some containing both estrogen and progestins, and some only containing progestin. Doses of component hormones also vary among products, and some pills are monophasic (delivering the same dose of hormones each day) while others are multiphasic (doses vary each day). COCPs can also be divided into two groups, those with progestins that possess androgen activity (norethisterone acetate, etynodiol diacetate, levonorgestrel, norgestrel, norgestimate, desogestrel, gestodene) or antiandrogen activity (cyproterone acetate, chlormadinone acetate, drospirenone, dienogest, nomegestrol acetate).

COCPs have been somewhat inconsistently grouped into "generations" in the medical literature based on when they were introduced.^[28][29]

• First generation COCPs are sometimes defined as those containing the progestins noretynodrel, norethisterone, norethisterone acetate, or etynodiol acetate;^[28] and sometimes defined as all COCPs containing ≥ 50 µg ethinylestradiol.^[29]
• Second generation COCPs are sometimes defined as those containing the progestins norgestrel or levonorgestrel;^[28] and sometimes defined as those containing the progestins norethisterone, norethisterone acetate, etynodiol acetate, norgestrel, levonorgestrel, or norgestimate and < 50 µg ethinylestradiol.^[29]
• Third generation COCPs are sometimes defined as those containing the progestins desogestrel or gestodene;^[29] and sometimes defined as those containing desogestrel, gestodene, or norgestimate.^[28]
• Fourth generation COCPs are sometimes defined as those containing the progestin drospirenone;^[28] and sometimes defined as those containing drospirenone, dienogest, or nomegestrol acetate.^[29]

Medical use

 

Half-used blister pack of LevlenED

Contraceptive use

Combined oral contraceptive pills are a type of oral medication that were originally designed to be taken every day at the same time of day in order to prevent pregnancy.^[30][31] There are many different formulations or brands, but the average pack is designed to be taken over a 28-day period (also known as a cycle). For the first 21 days of the cycle, users take a daily pill that contains two hormones, estrogen and progestogen. During the last 7 days of the cycle, users take daily placebo (biologically inactive) pills and these days are considered hormone-free days. Although these are hormone-free days, users are still protected from pregnancy during this time.

Some COCP packs only contain 21 pills and users are advised to take no pills for the last 7 days of the cycle.^[9] Other COCP formulations contain 91 pills, consisting of 84 days of active hormones followed by 7 days of placebo (Seasonale).^[30] Of recent innovation, COCP formulations can contain 24 days of active hormone pills followed by 4 days of placebo pills (e.g. Yaz 28 and Loestrin 24 Fe) as a means to decrease the severity of placebo effects.^[9] These COCPs containing active hormones and a placebo/hormone-free period are called cyclic COCPs. Once a pack of cyclical COCP treatment is completed, users start a new pack and new cycle.^[32]

Most monophasic COCPs can be used continuously such that patients can skip placebo days and continuously take hormone active pills from a COCP pack.^[9] One of the most common reasons users do this is to avoid or diminish withdrawal bleeding. The majority of women on cyclic COCPs have regularly scheduled withdrawal bleeding, which is vaginal bleeding mimicking users' menstrual cycles with the exception of lighter menstrual bleeding compared to bleeding patterns prior to COCP commencement. As such, a recent study reported that out of 1003 women taking COCPs approximately 90% reported regularly scheduled withdrawal bleeds over a 90-day standard reference period.^[9] Withdrawal bleeding usually occurs during the placebo, hormone-free days. Therefore, avoiding placebo days can diminish withdrawal bleeding among other placebo effects.

Effectiveness

If used exactly as instructed, the estimated risk of getting pregnant is 0.3% which means that about 3 in 1000 women on COCPs will become pregnant within one year.^[33] However, typical use of COCPs by users often consists of timing errors, forgotten pills, or unwanted side effects. With typical use, the estimated risk of getting pregnant is about 9% which means that about 9 in 100 women on COCPs will become pregnant in one year.^[34] The perfect use failure rate is based on a review of pregnancy rates in clinical trials, and the typical use failure rate is based on a weighted average of estimates from the 1995 and 2002 U.S. National Surveys of Family Growth (NSFG), corrected for underreporting of abortions.^[35][36]

Several factors account for typical use effectiveness being lower than perfect use effectiveness:

1. Mistakes on part of those providing instructions on how to use the method
2. Mistakes on part of the user
3. Conscious user non-compliance with instructions

For instance, someone using COCPs might have received incorrect information by a health care provider about medication frequency, forgotten to take the pill one day or not gone to the pharmacy in time to renew her COCP prescription.

COCPs provide effective contraception from the very first pill if started within five days of the beginning of the menstrual cycle (within five days of the first day of menstruation). If started at any other time in the menstrual cycle, COCPs provide effective contraception only after 7 consecutive days of use of active pills, so a backup method of contraception (e.g. condoms) must be used in the interim.^[37][38]

The effectiveness of COCPs appears to be similar whether the active pills are taken continuously or if they are taken cyclically.^[39] Contraceptive efficacy, however, could be impaired by numerous means. Factors that may contribute to a decrease in effectiveness:^[37]

1. Missing more than one active pill in a packet,
2. Delay in starting the next packet of active pills (i.e., extending the pill-free, inactive pill or placebo pill period beyond 7 days),
3. Intestinal malabsorption of active pills due to vomiting or diarrhea,
4. Drug-drug interactions among COCPs and other medications of the user that decrease contraceptive estrogen and/or progestogen levels.^[37]

In any of these instances, a backup contraceptive method should be used until hormone active pills have been consistently taken for 7 consecutive days or drug-drug interactions or underlying illnesses have been discontinued or resolved.^[37] According to CDC guidelines, a pill is considered "late" if a user takes the pill after the user's normal medication time, but no longer than 24 hours after this normal time. If 24 hours or more have passed since the time the user was supposed to take the pill, then the pill is considered "missed."^[33] CDC guidelines discuss potential next steps for users who missed their pill or took it late.^[40]

Role of placebo pills

The role of the placebo pills is two-fold: to allow the user to continue the routine of taking a pill every day and to simulate the average menstrual cycle. By continuing to take a pill every day, users remain in the daily habit even during the week without hormones. Failure to take pills during the placebo week does not impact the effectiveness of the pill, provided that daily ingestion of active pills is resumed at the end of the week.^[41]

The placebo, or hormone-free, week in the 28-day pill package simulates an average menstrual cycle, though the hormonal events during a pill cycle are significantly different from those of a normal ovulatory menstrual cycle. Because the pill suppresses ovulation (to be discussed more in the Mechanism of action section), birth control users do not have true menstrual periods. Instead, it is the lack of hormones for a week that causes a withdrawal bleed.^[31] The withdrawal bleeding that occurs during the break from active pills has been thought to be reassuring, a physical confirmation of not being pregnant.^[42] The withdrawal bleeding is also predictable. Unexpected breakthrough bleeding can be a possible side effect of longer term active regimens.^[43]

Since it is not uncommon for menstruating women to become anemic, some placebo pills may contain an iron supplement.^[44][45] This replenishes iron stores that may become depleted during menstruation. As well, birth control pills, such as COCPs, are sometimes fortified with folic acid as it is recommended to take folic acid supplementation in the months prior to pregnancy to decrease the likelihood of neural tube defect in infants.^[46][47]

No or less frequent placebos

Main article: Extended cycle combined oral contraceptive pill

If the pill formulation is monophasic, meaning each hormonal pill contains a fixed dose of hormones, it is possible to skip withdrawal bleeding and still remain protected against conception by skipping the placebo pills altogether and starting directly with the next packet. Attempting this with bi- or tri-phasic pill formulations carries an increased risk of breakthrough bleeding and may be undesirable. It will not, however, increase the risk of getting pregnant.

Starting in 2003, women have also been able to use a three-month version of the pill.^[48] Similar to the effect of using a constant-dosage formulation and skipping the placebo weeks for three months, Seasonale gives the benefit of less frequent periods, at the potential drawback of breakthrough bleeding. Seasonique is another version in which the placebo week every three months is replaced with a week of low-dose estrogen.

A version of the combined pill has also been packaged to eliminate placebo pills and withdrawal bleeds. Marketed as Anya or Lybrel, studies have shown that after seven months, 71% of users no longer had any breakthrough bleeding, the most common side effect of going longer periods of time without breaks from active pills.

While more research needs to be done to assess the long term safety of using COCP's continuously, studies have shown there may be no difference in short term adverse effects when comparing continuous use versus cyclic use of birth control pills.^[39]

Non-contraceptive use

The hormones in the pill have also been used to treat other medical conditions, such as polycystic ovary syndrome (PCOS), endometriosis, adenomyosis, acne, hirsutism, amenorrhea, menstrual cramps, menstrual migraines, menorrhagia (excessive menstrual bleeding), menstruation-related or fibroid-related anemia and dysmenorrhea (painful menstruation).^[34][49] Besides acne, no oral contraceptives have been approved by the U.S. FDA for the previously mentioned uses despite extensive use for these conditions.^[50]

PCOS

The cause of PCOS, or polycystic ovary syndrome, is multifactorial and not well-understood. Women with PCOS often have higher than normal levels of luteinizing hormone (LH) and androgens that impact the normal function of the ovaries.^[51] While multiple small follicles develop in the ovary, none are able to grow in size enough to become the dominant follicle and trigger ovulation.^[52] This leads to an imbalance of LH, follicle stimulating hormone, estrogen, and progesterone. Without ovulation, unopposed estrogen can lead to endometrial hyperplasia, or overgrowth of tissue in the uterus.^[53] This endometrial overgrowth is more likely to become cancerous than normal endometrial tissue.^[54] Thus, although the data varies, it is generally agreed upon by most gynecological societies that due to the unopposed estrogen, women with PCOS are at higher risk for endometrial cancer.^[55]

To reduce the risk of endometrial cancer, it is often recommended that women with PCOS who do not desire pregnancy take hormonal contraceptives to prevent the effects of unopposed estrogen. Both COCPs and progestin-only methods are recommended.^[56] It is the progestin component of COCPs that protects the endometrium from hyperplasia, and thus reduces a woman with PCOS's endometrial cancer risk.^[57] COCPs are preferred to progestin-only methods in women who also have uncontrolled acne, symptoms of hirsutism, and androgenic alopecia, because COCPs can help treat these symptoms.^[31]

Acne and hirsutism

COCPs are sometimes prescribed to treat symptoms of androgenization, including acne and hirsutism.^[58] The estrogen component of COCPs appears to suppress androgen production in the ovaries. Estrogen also leads to increased synthesis of sex hormone binding globulin, which causes a decrease in the levels of free testosterone.^[59]

Ultimately, the drop in the level of free androgens leads to a decrease in the production of sebum, which is a major contributor to development of acne.^[60] Four different oral contraceptives have been FDA approved to treat moderate acne if the patient is at least 14 or 15 years old, has already begun menstruating, and needs contraception. These include Ortho Tri-Cyclen, Estrostep, Beyaz, and YAZ.^[61][62][63]

Hirsutism is the growth of coarse, dark hair where women typically grow only fine hair or no hair at all.^[64] This hair growth on the face, chest, and abdomen is also mediated by higher levels or action of androgens. Therefore, COCPs also work to treat these symptoms by lowering the levels of free circulating androgens.^[65]

Endometriosis

For pelvic pain associated with endometriosis, COCPs are considered a first-line medical treatment, along with NSAIDs, GnRH agonists, and aromatase inhibitors.^[66] COCPs work to suppress the growth of the extra-uterine endometrial tissue. This works to lessen its inflammatory effects.^[31] COCPs, along with the other medical treatments listed above, do not eliminate the extra-uterine tissue growth, they just reduce the symptoms. Surgery is the only definitive treatment. Studies looking at rates of pelvic pain recurrence after surgery have shown that continuous use of COCPs is more effective at reducing the recurrence of pain than cyclic use.^[67]

Adenomyosis

Similar to endometriosis, adenomyosis is often treated with COCPs to suppress the growth the endometrial tissue that has grown into the myometrium. Unlike endometriosis however, levonorgetrel containing IUDs are more effective at reducing pelvic pain in adenomyosis than COCPs.^[31]

Menorrhagia

In the average menstrual cycle, a woman typically loses 35 to 40 milliliters of blood.^[68] However, up to 20% of women experience much heavier bleeding, or menorrhagia.^[69] This excess blood loss can lead to anemia, with symptoms of fatigue and weakness, as well as disruption in their normal life activities.^[70] COCPs contain progestin, which causes the lining of the uterus to be thinner, resulting in lighter bleeding episodes for those with heavy menstrual bleeding.^[71]

Amenorrhea

Although the pill is sometimes prescribed to induce menstruation on a regular schedule for women bothered by irregular menstrual cycles, it actually suppresses the normal menstrual cycle and then mimics a regular 28-day monthly cycle.

Women who are experiencing menstrual dysfunction due to female athlete triad are sometimes prescribed oral contraceptives as pills that can create menstrual bleeding cycles.^[72] However, the condition's underlying cause is energy deficiency and should be treated by correcting the imbalance between calories eaten and calories burned by exercise. Oral contraceptives should not be used as an initial treatment for female athlete triad.^[72]

Contraindications

While combined oral contraceptives are generally considered to be a relatively safe medication, they are contraindicated for those with certain medical conditions. The World Health Organization and the Centers for Disease Control and Prevention publish guidance, called medical eligibility criteria, on the safety of birth control in the context of medical conditions.

Hypercoagulability

Estrogen in high doses can increase risk of blood clots. All COCP users have a small increase in the risk of venous thromboembolism compared with non-users; this risk is greatest within the first year of COCP use.^[73] Individuals with any pre-existing medical condition that also increases their risk for blood clots have a more significant increase in risk of thrombotic events with COCP use.^[73] These conditions include but are not limited to high blood pressure, pre-existing cardiovascular disease (such as valvular heart disease or ischemic heart disease^[74]), history of thromboembolism or pulmonary embolism, cerebrovascular accident, and a familial tendency to form blood clots (such as familial factor V Leiden).^[75] There are conditions that, when associated with COCP use, increase risk of adverse effects other than thrombosis. For example, women with a history of migraine with aura have an increased risk of stroke when using COCPs, and women who smoke over age 35 and use COCPs are at higher risk of myocardial infarction.^[76]

Pregnancy and postpartum

Women who are known to be pregnant should not take COCPs. Those in the postpartum period who are breastfeeding are also advised not to start COCPs until 4 weeks after birth due to increased risk of blood clots.^[33] While studies have demonstrated conflicting results about the effects of COCPs on lactation duration and milk volume, there exist concerns about the transient risk of COCPs on breast milk production when breastfeeding is being established early postpartum.^[77] Due to the stated risks and additional concerns on lactation, women who are breastfeeding are not advised to start COCPs until at least six weeks postpartum, while women who are not breastfeeding and have no other risks factors for blood clots may start COCPs after 21 days postpartum.^[78][76]

Breast cancer

The WHO currently does not recommend the use of COCPs in women with breast cancer.^[79] Since COCPs contain both estrogen and progestin, they are not recommended to be used in those with hormonally-sensitive cancers, including some types of breast cancer.^[80][81] Non-hormonal contraceptive methods, such as the Copper IUD or condoms,^[82] should be the first-line contraceptive choice for these patients instead of COCPs.^[83]

Other

Women with known or suspected endometrial cancer or unexplained uterine bleeding should also not take COCPs to avoid health risks.^[74] COCPs are also contraindicated for people with advanced diabetes, liver tumors, hepatic adenoma or severe cirrhosis of the liver.^[34][75] COCPs are metabolized in the liver and thus liver disease can lead to reduced elimination of the medication. Additionally, severe hypercholesterolemia and hypertriglyceridemia are also currently contraindications, but the evidence showing that COCP's lead to worse outcomes in this population is weak.^[31][33] Obesity is not considered to be a contraindication to taking COCPs.^[33]

Side effects

It is generally accepted that the health risks of oral contraceptives are lower than those from pregnancy and birth,^[84] and "the health benefits of any method of contraception are far greater than any risks from the method".^[85] Some organizations have argued that comparing a contraceptive method to no method (pregnancy) is not relevant—instead, the comparison of safety should be among available methods of contraception.^[86]

Common

Different sources note different incidence of side effects. The most common side effect is breakthrough bleeding. A 1992 French review article said that as many as 50% of new first-time users discontinue the birth control pill before the end of the first year because of the annoyance of side effects such as breakthrough bleeding and amenorrhea.^[87] A 2001 study by the Kinsey Institute exploring predictors of discontinuation of oral contraceptives found that 47% of 79 people discontinued the pill.^[88] One 1994 study found that women using birth control pills blinked 32% more often than those not using the contraception.^[89]

On the other hand, the pills can sometimes improve conditions such as dysmenorrhea, premenstrual syndrome, and acne,^[90] reduce symptoms of endometriosis and polycystic ovary syndrome, and decrease the risk of anemia.^[91] Use of oral contraceptives also reduces lifetime risk of ovarian and endometrial cancer.^[92][93][94] Women have experienced amenorrhea, easy administration, and improvement in sexual function in some patients.^[95]

Nausea, vomiting, headache, bloating, breast tenderness, swelling of the ankles/feet (fluid retention), or weight change may occur. Vaginal bleeding between periods (spotting) or missed/irregular periods may occur, especially during the first few months of use.^[96]

Heart and blood vessels

Combined oral contraceptives increase the risk of venous thromboembolism (including deep vein thrombosis (DVT) and pulmonary embolism (PE)).^[97]

While lower doses of estrogen in COC pills may have a lower risk of stroke and myocardial infarction compared to higher estrogen dose pills (50 μg/day), users of low estrogen dose COC pills still have an increased risk compared to non-users.^[98] These risks are greatest in women with additional risk factors, such as smoking (which increases risk substantially) and long-continued use of the pill, especially in women over 35 years of age.^[99]

The overall absolute risk of venous thrombosis per 100,000 woman-years in current use of combined oral contraceptives is approximately 60, compared with 30 in non-users.^[100] The risk of thromboembolism varies with different types of birth control pills; compared with combined oral contraceptives containing levonorgestrel (LNG), and with the same dose of estrogen and duration of use, the rate ratio of deep venous thrombosis for combined oral contraceptives with norethisterone is 0.98, with norgestimate 1.19, with desogestrel (DSG) 1.82, with gestodene 1.86, with drospirenone (DRSP) 1.64, and with cyproterone acetate 1.88.^[100] In comparison, venous thromboembolism occurs in 100–200 per 100.000 pregnant women every year.^[100]

One study showed more than a 600% increased risk of blood clots for women taking COCPs with drospirenone compared with non-users, compared with 360% higher for women taking birth control pills containing levonorgestrel.^[101] The U.S. Food and Drug Administration (FDA) initiated studies evaluating the health of more than 800,000 women taking COCPs and found that the risk of VTE was 93% higher for women who had been taking drospirenone COCPs for 3 months or less and 290% higher for women taking drospirenone COCPs for 7–12 months, compared with women taking other types of oral contraceptives.^[102]

Based on these studies, in 2012 the FDA updated the label for drospirenone COCPs to include a warning that contraceptives with drospirenone may have a higher risk of dangerous blood clots.^[103]

A 2015 systematic review and meta-analysis found that combined birth control pills were associated with 7.6-fold higher risk of cerebral venous sinus thrombosis, a rare form of stroke in which blood clotting occurs in the cerebral venous sinuses.^[104]

• v
• t
• e

Risk of venous thromboembolism (VTE) with hormone therapy and birth control (QResearch/CPRD)

Type	Route	Medications	Odds ratio (95% CI)
Menopausal hormone therapy	Oral	Estradiol alone     ≤1 mg/day     >1 mg/day	1.27 (1.16–1.39)* 1.22 (1.09–1.37)* 1.35 (1.18–1.55)*
		Conjugated estrogens alone     ≤0.625 mg/day     >0.625 mg/day	1.49 (1.39–1.60)* 1.40 (1.28–1.53)* 1.71 (1.51–1.93)*
		Estradiol/medroxyprogesterone acetate	1.44 (1.09–1.89)*
		Estradiol/dydrogesterone     ≤1 mg/day E2     >1 mg/day E2	1.18 (0.98–1.42) 1.12 (0.90–1.40) 1.34 (0.94–1.90)
		Estradiol/norethisterone     ≤1 mg/day E2     >1 mg/day E2	1.68 (1.57–1.80)* 1.38 (1.23–1.56)* 1.84 (1.69–2.00)*
		Estradiol/norgestrel or estradiol/drospirenone	1.42 (1.00–2.03)
		Conjugated estrogens/medroxyprogesterone acetate	2.10 (1.92–2.31)*
		Conjugated estrogens/norgestrel     ≤0.625 mg/day CEEs     >0.625 mg/day CEEs	1.73 (1.57–1.91)* 1.53 (1.36–1.72)* 2.38 (1.99–2.85)*
		Tibolone alone	1.02 (0.90–1.15)
		Raloxifene alone	1.49 (1.24–1.79)*
	Transdermal	Estradiol alone    ≤50 μg/day    >50 μg/day	0.96 (0.88–1.04) 0.94 (0.85–1.03) 1.05 (0.88–1.24)
		Estradiol/progestogen	0.88 (0.73–1.01)
	Vaginal	Estradiol alone	0.84 (0.73–0.97)
		Conjugated estrogens alone	1.04 (0.76–1.43)
Combined birth control	Oral	Ethinylestradiol/norethisterone	2.56 (2.15–3.06)*
		Ethinylestradiol/levonorgestrel	2.38 (2.18–2.59)*
		Ethinylestradiol/norgestimate	2.53 (2.17–2.96)*
		Ethinylestradiol/desogestrel	4.28 (3.66–5.01)*
		Ethinylestradiol/gestodene	3.64 (3.00–4.43)*
		Ethinylestradiol/drospirenone	4.12 (3.43–4.96)*
		Ethinylestradiol/cyproterone acetate	4.27 (3.57–5.11)*
Notes: (1) Nested case–control studies (2015, 2019) based on data from the QResearch and Clinical Practice Research Datalink (CPRD) databases. (2) Bioidentical progesterone was not included, but is known to be associated with no additional risk relative to estrogen alone. Footnotes: * = Statistically significant (p < 0.01). Sources: See template.

Cancer

Decreased risk of ovarian, endometrial, and colorectal cancers

Usage of combined oral concetraption decreased the risk of ovarian cancer, endometrial cancer,^[37] and colorectal cancer.^[4][90][105] Two large cohort studies published in 2010 both found a significant reduction in adjusted relative risk of ovarian and endometrial cancer mortality in ever-users of OCs compared with never-users.^[2][106] The use of oral contraceptives (birth control pills) for five years or more decreases the risk of ovarian cancer in later life by 50%.^[105][107] Combined oral contraceptive use reduces the risk of ovarian cancer by 40% and the risk of endometrial cancer by 50% compared with never users. The risk reduction increases with duration of use, with an 80% reduction in risk for both ovarian and endometrial cancer with use for more than 10 years. The risk reduction for both ovarian and endometrial cancer persists for at least 20 years.^[37]

Increased risk of breast, cervical, and liver cancers

A report by a 2005 International Agency for Research on Cancer (IARC) working group found that COCs increase the risk of cancers of the breast, cervix and liver.^[4] A systematic review in 2010 did not support an increased overall cancer risk in users of combined oral contraceptive pills, but did find a slight increase in breast cancer risk among current users, which disappears 5–10 years after use has stopped; the study also found an increased risk of cervical and liver cancers.^[108] A 2013 meta-analysis concluded that every use of birth control pills is associated with a modest increase in the risk of breast cancer (relative risk 1.08) and a reduced risk of colorectal cancer (relative risk 0.86) and endometrial cancer (relative risk 0.57). Cervical cancer risk in those infected with HPV is increased.^[109] A similar small increase in breast cancer risk was observed in other meta analyses.^[110][111] A study of 1.8 million Danish women of reproductive age followed for 11 years found that the risk of breast cancer was 20% higher among those who currently or recently used hormonal contraceptives than among women who had never used hormonal contraceptives.^[112] This risk increased with duration of use, with a 38% increase in risk after more than 10 years of use.^[112]

Weight

A 2016 Cochrane systematic review found low quality evidence that studies of combination hormonal contraceptives showed no large difference in weight when compared with placebo or no intervention groups.^[113] The evidence was not strong enough to be certain that contraceptive methods do not cause some weight change, but no major effect was found.^{[114][needs update]} This review also found "that women did not stop using the pill or patch because of weight change."^[114]

Sexual function and risk aversion

COCPs may increase natural vaginal lubrication.^[115] Other women experience reductions in libido while on the pill, or decreased lubrication.^[115][116] Some researchers question a causal link between COCP use and decreased libido;^[117] a 2007 study of 1700 women found COCP users experienced no change in sexual satisfaction.^[118] A 2005 laboratory study of genital arousal tested fourteen women before and after they began taking COCPs. The study found that women experienced a significantly wider range of arousal responses after beginning pill use; decreases and increases in measures of arousal were equally common.^[119][120]

Sexual desire

Main article: Effects of hormones on sexual motivation

See also: Gene-centered view of evolution, Automatic and controlled processes, Menstruation (mammal), and Sexual arousal

In 2012, The Journal of Sexual Medicine published a review of research studying the effects of hormonal contraceptives on female sexual function that concluded that the sexual side effects of hormonal contraceptives are not well-studied and especially in regards to impacts on libido, with research establishing only mixed effects where only small percentages of women report experiencing an increase or decrease and majorities report being unaffected.^[121] In 2013, The European Journal of Contraception & Reproductive Health Care published a review of 36 studies including 8,422 female subjects in total taking COCPs that found that 5,358 subjects (or 63.6 percent) reported no change in libido, 1,826 subjects (or 21.7 percent) reported an increase, and 1,238 subjects (or 14.7 percent) reported a decrease.^[122] In 2019, Neuroscience & Biobehavioral Reviews published a meta-analysis of 22 published and 4 unpublished studies (with 7,529 female subjects in total) that evaluated whether women expose themselves to greater health risks at different points in the menstrual cycle including by sexual activity with partners and found that subjects in the last third of the follicular phase and at ovulation (when levels of endogenous estradiol and luteinizing hormones are heightened) experienced increased sexual activity with partners.^[123]

A 2006 study of 124 premenopausal women measured sex hormone-binding globulin (SHBG), including before and after discontinuation of the oral contraceptive pill. Women continuing use of oral contraceptives had SHBG levels four times higher than those who never used it, and levels remained elevated even in the group that had discontinued its use.^[124][125] Theoretically, an increase in SHBG may be a physiologic response to increased hormone levels, but may decrease the free levels of other hormones, such as androgens, because of the unspecificity of its sex hormone binding. In 2020, The Lancet Diabetes & Endocrinology published a cross-sectional study of 588 premenopausal female subjects aged 18 to 39 years from the Australian states of Queensland, New South Wales, and Victoria with regular menstrual cycles whose SHBG levels were measured by immunoassay that found that after controlling for age, body mass index, cycle stage, smoking, parity, partner status, and psychoactive medication, SHBG was inversely correlated with sexual desire.^[126]

Decreased sexual attractiveness

See also: Sexual attraction, Concealed ovulation, Estrous cycle, Evolutionary mismatch, and Mating call

In 2004, the Proceedings of the Royal Society B: Biological Sciences published a study where pairs of digital photographs of the faces of 48 women at Newcastle University and Charles University between the ages 19 and 33 who were not taking hormonal contraceptives during the study were photographed in the late follicular and early mid-luteal phases of their menstrual cycles and the photographs were then rated by 261 subjects (130 male and 131 female) at their respective universities who compared the facial attractiveness of each photographed woman in their photograph pairs, and found that the subjects perceived the late follicular phase images of the photographed women as being more attractive than the luteal phase images by more than expected by random chance.^[127]

In 2007, Evolution and Human Behavior published a study where 18 professional lap dancers recorded their menstrual cycles, work shifts, and tip earnings at gentlemen's clubs for 60 days that found by a mixed model analysis of 296 work shifts (or approximately 5,300 lap dances) that the 11 dancers with normal menstrual cycles earned US$335 per 5-hour shift during the late follicular phase and at ovulation, US$260 per shift during the luteal phase, and US$185 per shift during menstruation, while the 7 dancers using hormonal contraceptives showed no earnings peak during the late follicular phase and at ovulation.^[128] In 2008, Evolution and Human Behavior published a study where the voices of 51 female students at the State University of New York at Albany were recorded with the women counting from 1 to 10 at four different points in their menstrual cycles were rated by subjects who listened to the recordings to be more attractive at the points of the menstrual cycle with higher probabilities of conception, while the ratings of the voices of the women who were taking hormonal contraceptives showed no variation over the menstrual cycle in attractiveness.^[129]

Decreased rape and sexual assault avoidance

See also: Behavioral modernity and Human factors

In 1998, Evolution and Human Behavior published a study of 300 female undergraduate students at the State University of New York at Albany between the ages of 18 and 54 (with a mean age of 21.9 years) that surveyed the subjects engagement in 18 different behaviors over the 24 hours prior to filling out the study's questionnaire that varied in their risk of potential rape or sexual assault and the first day of their last menstruations, and found that subjects at ovulation showed statistically significant decreased engagement in behaviors that risked rape and sexual assault while subjects taking birth control pills showed no variation over their menstrual cycles in the same behaviors (suggesting a psychologically adaptive function of the hormonal fluctuations during the menstrual cycle in causing avoidance of behaviors that risk rape and sexual assault).^[130][131] In 2003, Evolution and Human Behavior published a conceptual replication study of the 1998 survey that confirmed its findings.^[132]

In 2006, a study presented at the annual conference of the Cognitive Science Society surveyed 176 female undergraduate students at Michigan State University (with a mean age of 19.9 years) in a decision-making experiment where the subjects chose between an option with a guaranteed outcome or an option involving risk and indicated the first day of their last menstruations, and found that the subjects risk aversion preferences varied over the menstrual cycle (with none of the subjects at ovulation preferring the risky option) and only subjects not taking hormonal contraceptives showed the menstrual cycle effect on risk aversion.^[133] In the 2019 Neuroscience & Biobehavioral Reviews meta-analysis, the research reviewed also evaluated whether the 7,529 female subjects across the 26 studies showed greater risk recognition and avoidance of potentially threatening people and dangerous situations at different phases of the menstrual cycle and found that the subjects displayed better risk accuracy recognition during the late follicular phase and at ovulation as compared to the luteal phase.^[123]

Depression

Low levels of serotonin, a neurotransmitter in the brain, have been linked to depression. High levels of estrogen, as in first-generation COCPs, and progestin, as in some progestin-only contraceptives, have been shown to lower the brain serotonin levels by increasing the concentration of a brain enzyme that reduces serotonin. A growing body of research evidence has suggested that hormonal contraception may have an adverse effect on women's psychological health.^{[134][135][136]} In 2016, a large Danish study of one million women (followed-up from January 2000 to December 2013) showed that use of COCPs, especially among adolescents, was associated with a statistically significantly increased risk of subsequent depression, although the sizes of the effects are small (for example, 2.1% of the women who took any form of oral birth control were prescribed anti-depressants for the first time, compared to 1.7% of women in the control group).^[135] Similarly, in 2018, the findings from a large nationwide Swedish cohort study investigating the effect of hormonal contraception on mental health amongst women (n=815,662, aged 12–30) were published, highlighting an association between hormonal contraception and subsequent use of psychotropic drugs for women of reproductive age.^[136] This association was particularly large for young adolescents (aged 12–19).^[136] The authors call for further research into the influence of different kinds of hormonal contraception on young women's psychological health.^[136]

Progestin-only contraceptives are known to worsen the condition of women who are already depressed.^[137][138] However, current medical reference textbooks on contraception^[37] and major organizations such as the American ACOG,^[139] the WHO,^[140] and the United Kingdom's RCOG^[141] agree that current evidence indicates low-dose combined oral contraceptives are unlikely to increase the risk of depression, and unlikely to worsen the condition in women that are currently depressed.

Hypertension

Bradykinin lowers blood pressure by causing blood vessel dilation. Certain enzymes are capable of breaking down bradykinin (Angiotensin Converting Enzyme, Aminopeptidase P). Progesterone can increase the levels of Aminopeptidase P (AP-P), thereby increasing the breakdown of bradykinin, which increases the risk of developing hypertension.^[142]

Other effects

Other side effects associated with low-dose COCPs are leukorrhea (increased vaginal secretions), reductions in menstrual flow, mastalgia (breast tenderness), and decrease in acne. Side effects associated with older high-dose COCPs include nausea, vomiting, increases in blood pressure, and melasma (facial skin discoloration); these effects are not strongly associated with low-dose formulations.^{[medical citation needed]}

Excess estrogen, such as from birth control pills, appears to increase cholesterol levels in bile and decrease gallbladder movement, which can lead to gallstones.^[143] Progestins found in certain formulations of oral contraceptive pills can limit the effectiveness of weight training to increase muscle mass.^[144] This effect is caused by the ability of some progestins to inhibit androgen receptors. One study claims that the pill may affect what male body odors a woman prefers, which may in turn influence her selection of partner.^{[145][146][147]} Use of combined oral contraceptives is associated with a reduced risk of endometriosis, giving a relative risk of endometriosis of 0.63 during active use, yet with limited quality of evidence according to a systematic review.^[148]

Combined oral contraception decreases total testosterone levels by approximately 0.5 nmol/L, free testosterone by approximately 60%, and increases the amount of sex hormone binding globulin (SHBG) by approximately 100 nmol/L. Contraceptives containing second generation progestins and/or estrogen doses of around 20 –25 mg EE were found to have less impact on SHBG concentrations.^[149] Combined oral contraception may also reduce bone density.^[150]

Drug interactions

Some drugs reduce the effect of the pill and can cause breakthrough bleeding, or increased chance of pregnancy. These include drugs such as rifampicin, barbiturates, phenytoin and carbamazepine. In addition cautions are given about broad spectrum antibiotics, such as ampicillin and doxycycline, which may cause problems "by impairing the bacterial flora responsible for recycling ethinylestradiol from the large bowel" (BNF 2003).^{[151][152][153][154]}

The traditional medicinal herb St John's Wort has also been implicated due to its upregulation of the P450 system in the liver which could increase the metabolism of ethinyl estradiol and progestin components of some combined oral contraception.^[155]

History

Introduction of first-generation birth control pills

Progestin	Estrogen	Brand name	Manufacturer	U.S.	U.K.
Noretynodrel	Mestranol	Enovid (US) Conovid (UK)	Searle	1960	1961
Norethisterone	Mestranol	Ortho-Novum Norinyl	Syntex and Ortho	1963	1966
Norethisterone	Ethinylestradiol	Norlestrin	Syntex and Parke-Davis	1964	1962
Lynestrenol	Mestranol	Lyndiol	Organon	–	1963
Megestrol acetate	Ethinylestradiol	Volidan Nuvacon	BDH	–	1963
Norethisterone acetate	Ethinylestradiol	Norlestrin	Parke-Davis	1964	?
Quingestanol acetate	Ethinylestradiol	Riglovis	Vister	–	–
Quingestanol acetate	Quinestrol	Unovis	Warner Chilcott	–	–
Medroxyprogesterone acetate	Ethinylestradiol	Provest	Upjohn	1964	–
Chlormadinone acetate	Mestranol	C-Quens	Merck	1965	1965
Dimethisterone	Ethinylestradiol	Oracon	BDH	1965	–
Etynodiol diacetate	Mestranol	Ovulen	Searle	1966	1965
Etynodiol diacetate	Ethinylestradiol	Demulen	Searle	1970	1968
Norgestrienone	Ethinylestradiol	Planor Miniplanor	Roussel Uclaf	–	–
Norgestrel	Ethinylestradiol	Ovral	Wyeth	1968	1972
Anagestone acetate	Mestranol	Neo-Novum	Ortho	–	–
Lynestrenol	Ethinylestradiol	Lyndiol	Organon	–	1969
Sources: ^[156]^[157]^[158]^[159]^[160]^[161]^[162]

By the 1930s, scientists had isolated and determined the structure of the steroid hormones and found that high doses of androgens, estrogens or progesterone inhibited ovulation,^{[163][164][165][166]} but obtaining these hormones, which were produced from animal extracts, from European pharmaceutical companies was extraordinarily expensive.^[167]

In 1939, Russell Marker, a professor of organic chemistry at Pennsylvania State University, developed a method of synthesizing progesterone from plant steroid sapogenins, initially using sarsapogenin from sarsaparilla, which proved too expensive. After three years of extensive botanical research, he discovered a much better starting material, the saponin from inedible Mexican yams (Dioscorea mexicana and Dioscorea composita) found in the rain forests of Veracruz near Orizaba. The saponin could be converted in the lab to its aglycone moiety diosgenin. Unable to interest his research sponsor Parke-Davis in the commercial potential of synthesizing progesterone from Mexican yams, Marker left Penn State and in 1944 co-founded Syntex with two partners in Mexico City. When he left Syntex a year later the trade of the barbasco yam had started and the period of the heyday of the Mexican steroid industry had been started. Syntex broke the monopoly of European pharmaceutical companies on steroid hormones, reducing the price of progesterone almost 200-fold over the next eight years.^{[168][169][170]}

Midway through the 20th century, the stage was set for the development of a hormonal contraceptive, but pharmaceutical companies, universities and governments showed no interest in pursuing research.^[171]

Progesterone to prevent ovulation

Progesterone, given by injections, was first shown to inhibit ovulation in animals in 1937 by Makepeace and colleagues.^[172]

In early 1951, reproductive physiologist Gregory Pincus, a leader in hormone research and co-founder of the Worcester Foundation for Experimental Biology (WFEB) in Shrewsbury, Massachusetts, first met American birth control movement founder Margaret Sanger at a Manhattan dinner hosted by Abraham Stone, medical director and vice president of Planned Parenthood (PPFA), who helped Pincus obtain a small grant from PPFA to begin hormonal contraceptive research.^{[173][174][175]} Research started on April 25, 1951, with reproductive physiologist Min Chueh Chang repeating and extending the 1937 experiments of Makepeace et al. that was published in 1953 and showed that injections of progesterone suppressed ovulation in rabbits.^[172] In October 1951, G. D. Searle & Company refused Pincus' request to fund his hormonal contraceptive research, but retained him as a consultant and continued to provide chemical compounds to evaluate.^{[167][176][177]}

In March 1952, Sanger wrote a brief note mentioning Pincus' research to her longtime friend and supporter, suffragist and philanthropist Katharine Dexter McCormick, who visited the WFEB and its co-founder and old friend Hudson Hoagland in June 1952 to learn about contraceptive research there. Frustrated when research stalled from PPFA's lack of interest and meager funding, McCormick arranged a meeting at the WFEB on June 6, 1953, with Sanger and Hoagland, where she first met Pincus who committed to dramatically expand and accelerate research with McCormick providing fifty times PPFA's previous funding.^[176][178]

Pincus and McCormick enlisted Harvard clinical professor of gynecology John Rock, chief of gynecology at the Free Hospital for Women and an expert in the treatment of infertility, to lead clinical research with women. At a scientific conference in 1952, Pincus and Rock, who had known each other for many years, discovered they were using similar approaches to achieve opposite goals. In 1952, Rock induced a three-month anovulatory "pseudopregnancy" state in eighty of his infertility patients with continuous gradually increasing oral doses of an estrogen (5 to 30 mg/day diethylstilbestrol) and progesterone (50 to 300 mg/day), and within the following four months 15% of the women became pregnant.^{[176][179][180]}

In 1953, at Pincus' suggestion, Rock induced a three-month anovulatory "pseudopregnancy" state in twenty-seven of his infertility patients with an oral 300 mg/day progesterone-only regimen for 20 days from cycle days 5–24 followed by pill-free days to produce withdrawal bleeding.^[181] This produced the same 15% pregnancy rate during the following four months without the amenorrhea of the previous continuous estrogen and progesterone regimen.^[181] But 20% of the women experienced breakthrough bleeding and in the first cycle ovulation was suppressed in only 85% of the women, indicating that even higher and more expensive oral doses of progesterone would be needed to initially consistently suppress ovulation.^[181] Similarly, Ishikawa and colleagues found that ovulation inhibition occurred in only a "proportion" of cases with 300 mg/day oral progesterone.^[182] Despite the incomplete inhibition of ovulation by oral progesterone, no pregnancies occurred in the two studies, although this could have simply been due to chance.^[182][183] However, Ishikawa et al. reported that the cervical mucus in women taking oral progesterone became impenetrable to sperm, and this may have accounted for the absence of pregnancies.^[182][183]

Progesterone was abandoned as an oral ovulation inhibitor following these clinical studies due to the high and expensive doses required, incomplete inhibition of ovulation, and the frequent incidence of breakthrough bleeding.^[172][184] Instead, researchers would turn to much more potent synthetic progestogens for use in oral contraception in the future.^[172][184]

Progestins to prevent ovulation

Pincus asked his contacts at pharmaceutical companies to send him chemical compounds with progestogenic activity. Chang screened nearly 200 chemical compounds in animals and found the three most promising were Syntex's norethisterone and Searle's noretynodrel and norethandrolone.^[185]

Chemists Carl Djerassi, Luis Miramontes, and George Rosenkranz at Syntex in Mexico City had synthesized the first orally highly active progestin norethisterone in 1951. Frank B. Colton at Searle in Skokie, Illinois had synthesized the orally highly active progestins noretynodrel (an isomer of norethisterone) in 1952 and norethandrolone in 1953.^[167]

In December 1954, Rock began the first studies of the ovulation-suppressing potential of 5–50 mg doses of the three oral progestins for three months (for 21 days per cycle—days 5–25 followed by pill-free days to produce withdrawal bleeding) in fifty of his patients with infertility in Brookline, Massachusetts. Norethisterone or noretynodrel 5 mg doses and all doses of norethandrolone suppressed ovulation but caused breakthrough bleeding, but 10 mg and higher doses of norethisterone or noretynodrel suppressed ovulation without breakthrough bleeding and led to a 14% pregnancy rate in the following five months. Pincus and Rock selected Searle's noretynodrel for the first contraceptive trials in women, citing its total lack of androgenicity versus Syntex's norethisterone very slight androgenicity in animal tests.^[186][187]

Combined oral contraceptive

Noretynodrel (and norethisterone) were subsequently discovered to be contaminated with a small percentage of the estrogen mestranol (an intermediate in their synthesis), with the noretynodrel in Rock's 1954–5 study containing 4–7% mestranol. When further purifying noretynodrel to contain less than 1% mestranol led to breakthrough bleeding, it was decided to intentionally incorporate 2.2% mestranol, a percentage that was not associated with breakthrough bleeding, in the first contraceptive trials in women in 1956. The noretynodrel and mestranol combination was given the proprietary name Enovid.^[187][188]

The first contraceptive trial of Enovid led by Celso-Ramón García and Edris Rice-Wray began in April 1956 in Río Piedras, Puerto Rico.^{[189][190][191]} A second contraceptive trial of Enovid (and norethisterone) led by Edward T. Tyler began in June 1956 in Los Angeles.^[170][192] On January 23, 1957, Searle held a symposium reviewing gynecologic and contraceptive research on Enovid through 1956 and concluded Enovid's estrogen content could be reduced by 33% to lower the incidence of estrogenic gastrointestinal side effects without significantly increasing the incidence of breakthrough bleeding.^[193]

While these large-scale trials contributed to the initial understanding of the pill formulation's clinical effects, the ethical implications of the trials generated significant controversy. Of note is the apparent lack of both autonomy and informed consent among participants in the Puerto Rican cohort prior to the trials. Many of these participants hailed from impoverished, working-class backgrounds.^[10]

Public availability

United States

 

Oral contraceptives, 1970s

On June 10, 1957, the Food and Drug Administration (FDA) approved Enovid 10 mg (9.85 mg noretynodrel and 150 µg mestranol) for menstrual disorders, based on data from its use by more than 600 women. Numerous additional contraceptive trials showed Enovid at 10, 5, and 2.5 mg doses to be highly effective. On July 23, 1959, Searle filed a supplemental application to add contraception as an approved indication for 10, 5, and 2.5 mg doses of Enovid. The FDA refused to consider the application until Searle agreed to withdraw the lower dosage forms from the application. On May 9, 1960, the FDA announced it would approve Enovid 10 mg for contraceptive use, and did so on June 23, 1960. At that point, Enovid 10 mg had been in general use for three years and, by conservative estimate, at least half a million women had used it.^{[191][194][195]}

Although FDA-approved for contraceptive use, Searle never marketed Enovid 10 mg as a contraceptive. Eight months later, on February 15, 1961, the FDA approved Enovid 5 mg for contraceptive use. In July 1961, Searle finally began marketing Enovid 5 mg (5 mg noretynodrel and 75 µg mestranol) to physicians as a contraceptive.^[194][196]

Although the FDA approved the first oral contraceptive in 1960, contraceptives were not available to married women in all states until Griswold v. Connecticut in 1965 and were not available to unmarried women in all states until Eisenstadt v. Baird in 1972.^[171][196]

The first published case report of a blood clot and pulmonary embolism in a woman using Enavid (Enovid 10 mg in the U.S.) at a dose of 20 mg/day did not appear until November 1961, four years after its approval, by which time it had been used by over one million women.^{[191][197][198]} It would take almost a decade of epidemiological studies to conclusively establish an increased risk of venous thrombosis in oral contraceptive users and an increased risk of stroke and myocardial infarction in oral contraceptive users who smoke or have high blood pressure or other cardiovascular or cerebrovascular risk factors.^[194] These risks of oral contraceptives were dramatized in the 1969 book The Doctors' Case Against the Pill by feminist journalist Barbara Seaman who helped arrange the 1970 Nelson Pill Hearings called by Senator Gaylord Nelson.^[199] The hearings were conducted by senators who were all men and the witnesses in the first round of hearings were all men, leading Alice Wolfson and other feminists to protest the hearings and generate media attention.^[196] Their work led to mandating the inclusion of patient package inserts with oral contraceptives to explain their possible side effects and risks to help facilitate informed consent.^{[200][201][202]} Today's standard dose oral contraceptives contain an estrogen dose that is one third lower than the first marketed oral contraceptive and contain lower doses of different, more potent progestins in a variety of formulations.^{[37][194][196]}

Beginning in 2015, certain states passed legislation allowing pharmacists to prescribe oral contraceptives. Such legislation was considered to address physician shortages and decrease barriers to birth control for women.^[203] Currently, pharmacists in Oregon, California, Colorado, Hawaii, Maryland, and New Mexico have authority to prescribe birth control after receiving specialized training and certification from their respective state Board of Pharmacy.^[204][205] Other states are considering this legislation, including Illinois, Minnesota, Missouri, and New Hampshire.^[203]

Australia

The first oral contraceptive introduced outside the United States was Schering's Anovlar (norethisterone acetate 4 mg + ethinylestradiol 50 µg) on January 1, 1961, in Australia.^[206]

Germany

The first oral contraceptive introduced in Europe was Schering's Anovlar on June 1, 1961, in West Germany.^[206] The lower hormonal dose, still in use, was studied by the Belgian Gynaecologist Ferdinand Peeters.^[207][208]

United Kingdom

Before the mid-1960s, the United Kingdom did not require pre-marketing approval of drugs. The British Family Planning Association (FPA) through its clinics was then the primary provider of family planning services in the UK and provided only contraceptives that were on its Approved List of Contraceptives (established in 1934). In 1957, Searle began marketing Enavid (Enovid 10 mg in the U.S.) for menstrual disorders. Also in 1957, the FPA established a Council for the Investigation of Fertility Control (CIFC) to test and monitor oral contraceptives which began animal testing of oral contraceptives and in 1960 and 1961 began three large clinical trials in Birmingham, Slough, and London.^[191][209]

In March 1960, the Birmingham FPA began trials of noretynodrel 2.5 mg + mestranol 50 µg, but a high pregnancy rate initially occurred when the pills accidentally contained only 36 µg of mestranol—the trials were continued with noretynodrel 5 mg + mestranol 75 µg (Conovid in the UK, Enovid 5 mg in the U.S.).^[210] In August 1960, the Slough FPA began trials of noretynodrel 2.5 mg + mestranol 100 µg (Conovid-E in the UK, Enovid-E in the U.S.).^[211] In May 1961, the London FPA began trials of Schering's Anovlar.^[212]

In October 1961, at the recommendation of the Medical Advisory Council of its CIFC, the FPA added Searle's Conovid to its Approved List of Contraceptives.^[213] On December 4, 1961, Enoch Powell, then Minister of Health, announced that the oral contraceptive pill Conovid could be prescribed through the NHS at a subsidized price of 2s per month.^[214][215] In 1962, Schering's Anovlar and Searle's Conovid-E were added to the FPA's Approved List of Contraceptives.^{[191][211][212]}

France

On December 28, 1967, the Neuwirth Law legalized contraception in France, including the pill.^[216] The pill is the most popular form of contraception in France, especially among young women. It accounts for 60% of the birth control used in France. The abortion rate has remained stable since the introduction of the pill.^[217]

Japan

In Japan, lobbying from the Japan Medical Association prevented the pill from being approved for general use for nearly 40 years. The higher dose "second generation" pill was approved for use in cases of gynecological problems, but not for birth control. Two main objections raised by the association were safety concerns over long-term use of the pill, and concerns that pill use would lead to decreased use of condoms and thereby potentially increase sexually transmitted infection (STI) rates.^[218]

However, when the Ministry of Health and Welfare approved Viagra's use in Japan after only six months of the application's submission, while still claiming that the pill required more data before approval, women's groups cried foul.^[219] The pill was subsequently approved for use in June 1999, when Japan became the last UN member country to do so.^[220] However, the pill has not become popular in Japan.^[221] According to estimates, only 1.3 percent of 28 million Japanese females of childbearing age use the pill, compared with 15.6 percent in the United States. The pill prescription guidelines the government has endorsed require pill users to visit a doctor every three months for pelvic examinations and undergo tests for sexually transmitted diseases and uterine cancer. In the United States and Europe, in contrast, an annual or bi-annual clinic visit is standard for pill users. However, beginning as far back as 2007, many Japanese OBGYNs have required only a yearly visit for pill users, with multiple checks a year recommended only for those who are older or at increased risk of side effects.^[222] As of 2004, condoms accounted for 80% of birth control use in Japan, and this may explain Japan's comparatively low rates of AIDS.^[222]

Society and culture

The pill was approved by the FDA in the early 1960s; its use spread rapidly in the late part of that decade, generating an enormous social impact. Time magazine placed the pill on its cover in April, 1967.^[223][224] In the first place, it was more effective than most previous reversible methods of birth control, giving women unprecedented control over their fertility.^[225] Its use was separate from intercourse, requiring no special preparations at the time of sexual activity that might interfere with spontaneity or sensation, and the choice to take the pill was a private one. This combination of factors served to make the pill immensely popular within a few years of its introduction.^[168][196]

Claudia Goldin, among others, argue that this new contraceptive technology was a key player in forming women's modern economic role, in that it prolonged the age at which women first married allowing them to invest in education and other forms of human capital as well as generally become more career-oriented. Soon after the birth control pill was legalized, there was a sharp increase in college attendance and graduation rates for women.^[226] From an economic point of view, the birth control pill reduced the cost of staying in school. The ability to control fertility without sacrificing sexual relationships allowed women to make long term educational and career plans.^[227]

Because the pill was so effective, and soon so widespread, it also heightened the debate about the moral and health consequences of pre-marital sex and promiscuity. Never before had sexual activity been so divorced from reproduction. For a couple using the pill, intercourse became purely an expression of love, or a means of physical pleasure, or both; but it was no longer a means of reproduction. While this was true of previous contraceptives, their relatively high failure rates and their less widespread use failed to emphasize this distinction as clearly as did the pill. The spread of oral contraceptive use thus led many religious figures and institutions to debate the proper role of sexuality and its relationship to procreation. The Roman Catholic Church in particular, after studying the phenomenon of oral contraceptives, re-emphasized the stated teaching on birth control in the 1968 papal encyclical Humanae vitae. The encyclical reiterated the established Catholic teaching that artificial contraception distorts the nature and purpose of sex.^[228] On the other side Anglican and other Protestant churches, such as the Evangelical Church in Germany (EKD), accepted the combined oral contraceptive pill.^[229]

The United States Senate began hearings on the pill in 1970 and where different viewpoints were heard from medical professionals. Dr. Michael Newton, President of the College of Obstetricians and Gynecologists said:

The evidence is not yet clear that these still do in fact cause cancer or related to it. The FDA Advisory Committee made comments about this, that if there wasn't enough evidence to indicate whether or not these pills were related to the development of cancer, and I think that's still thin; you have to be cautious about them, but I don't think there is clear evidence, either one way or the other, that they do or don't cause cancer.^[230]

Another physician, Dr. Roy Hertz of the Population Council, said that anyone who takes this should know of "our knowledge and ignorance in these matters" and that all women should be made aware of this so they can decide to take the pill or not.^[230]

The Secretary of Health, Education, and Welfare at the time, Robert Finch, announced the federal government had accepted a compromise warning statement which would accompany all sales of birth control pills.^[230]

Result on popular culture

The introduction of the birth control pill in 1960 allowed more women to find employment opportunities and further their education. As a result of women getting more jobs and an education, their husbands had to start taking over household tasks like cooking.^[231] Wanting to stop the change that was occurring in terms of gender norms in an American household, many films, television shows, and other popular culture items portrayed what an ideal American family should be. Below are listed some examples:

Poem

• The Pill Versus the Springhill Mine Disaster was the title poem of a 1968 collection by Richard Brautigan.^[232]

Music

• Singer Loretta Lynn commented on how women no longer had to choose between a relationship and a career in her 1974 album with a song entitled "The Pill", which told the story of a married woman's use of the drug to liberate herself from her traditional role as wife and mother.^[233]

Environmental impact

A woman using COCPs excretes from her urine and feces natural estrogens, estrone (E1) and estradiol (E2), and synthetic estrogen ethinylestradiol (EE2).^[234] These hormones can pass through water treatment plants and into rivers.^[235] Other forms of contraception, such as the contraceptive patch, use the same synthetic estrogen (EE2) that is found in COCPs, and can add to the hormonal concentration in the water when flushed down the toilet.^[236] This excretion is shown to play a role in causing endocrine disruption, which affects the sexual development and reproduction of wild fish populations in segments of streams contaminated by treated sewage effluents.^[234][237] A study done in British rivers supported the hypothesis that the incidence and the severity of intersex wild fish populations were significantly correlated with the concentrations of the E1, E2, and EE2 in the rivers.^[234]

A review of activated sludge plant performance found estrogen removal rates varied considerably but averaged 78% for estrone, 91% for estradiol, and 76% for ethinylestradiol (estriol effluent concentrations are between those of estrone and estradiol, but estriol is a much less potent endocrine disruptor to fish).^[238]

Several studies have suggested that reducing human population growth through increased access to contraception, including birth control pills, can be an effective strategy for climate change mitigation as well as adaptation.^[239][240] According to Thomas Wire, contraception is the 'greenest technology' because of its cost-effectiveness in combating global warming — each $7 spent on contraceptives would reduce global carbon emissions by 1 tonne over four decades, while achieving the same result with low-carbon technologies would require $32.^[241]

See also

• Estradiol-containing oral contraceptive
• Hormone replacement therapy (HRT)
• List of estrogens available in the United States
• List of progestogens available in the United States
• Progestogen-only injectable contraceptive

References

1. Trussell J (2011). "Contraceptive efficacy". In Hatcher RA, Trussell J, Nelson A, Cates W, Kowal D, Policar M (eds.). Contraceptive technology (20th revised ed.). New York: Ardent Media. pp. 779–863. ISBN 978-1-59708-004-0. ISSN 0091-9721. OCLC 781956734. Table 26–1 = Table 3–2 Percentage of women experiencing an unintended pregnancy during the first year of typical use and the first year of perfect use of contraception, and the percentage continuing use at the end of the first year. United States. 2017-02-15 at the Wayback Machine
2. Hannaford PC, Iversen L, Macfarlane TV, Elliott AM, Angus V, Lee AJ (March 2010). "Mortality among contraceptive pill users: cohort evidence from Royal College of General Practitioners' Oral Contraception Study". BMJ. 340: c927. doi:10.1136/bmj.c927. PMC 2837145. PMID 20223876.
3. "Oral Contraceptives and Cancer Risk". National Cancer Institute. 22 Feb 2018. Retrieved 10 May 2020.
4. IARC working group (2007). "Combined Estrogen-Progestogen Contraceptives" (PDF). IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. 91.
5. Collaborative Group on Hormonal Factors in Breast Cancer (June 1996). . Lancet. 347 (9017): 1713–27. doi:10.1016/S0140-6736(96)90806-5. PMID 8656904. S2CID 36136756. Archived from the original on 2019-01-23. Retrieved 2018-12-16.
6. Kemmeren JM, Tanis BC, van den Bosch MA, Bollen EL, Helmerhorst FM, van der Graaf Y, Rosendaal FR, Algra A (May 2002). "Risk of Arterial Thrombosis in Relation to Oral Contraceptives (RATIO) study: oral contraceptives and the risk of ischemic stroke". Stroke. 33 (5): 1202–8. doi:10.1161/01.STR.0000015345.61324.3F. PMID 11988591.
7. Baillargeon JP, McClish DK, Essah PA, Nestler JE (July 2005). "Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis". The Journal of Clinical Endocrinology and Metabolism. 90 (7): 3863–70. doi:10.1210/jc.2004-1958. PMID 15814774.
8. "Birth Control Pills - Birth Control Pill - The Pill".
9. Teal S, Edelman A (December 2021). "Contraception Selection, Effectiveness, and Adverse Effects: A Review". JAMA. 326 (24): 2507–2518. doi:10.1001/jama.2021.21392. PMID 34962522. S2CID 245557522.
10. "Guinea pigs or pioneers? How Puerto Rican women were used to test the birth control pill". Washington Post. ISSN 0190-8286. Retrieved 2022-09-14.
11. "Birth Control Pill (for Teens) - Nemours KidsHealth". kidshealth.org. Retrieved 2022-09-21.
12. Contraceptive use by method 2019 : data booklet. [New York, NY]: United Nations. Department of Economic and Social Affairs. Population Division. 2019. ISBN 978-92-1-148329-1. OCLC 1135665739.
13. Christin-Maitre S (February 2013). "History of oral contraceptive drugs and their use worldwide". Best Practice & Research. Clinical Endocrinology & Metabolism. 27 (1): 3–12. doi:10.1016/j.beem.2012.11.004. PMID 23384741.
14. "Products - Data Briefs - Number 327 - December 2018". www.cdc.gov. 2022-07-11. Retrieved 2022-09-14.
15. Sech LA, Mishell DR (November 2015). "Oral steroid contraception". Women's Health. 11 (6): 743–748. doi:10.2217/whe.15.82. PMID 26673988. S2CID 6433771.
16. "Current Contraceptive Status Among Women Aged 15–49: United States, 2015–2017". www.cdc.gov. 2019-06-07. Retrieved 2019-08-02.
17. UN Population Division (2006). World Contraceptive Use 2005 (PDF). New York: United Nations. ISBN 978-92-1-151418-6. women aged 15–49 married or in consensual union
18. Delvin D (2016-06-15). "Contraception – the contraceptive pill: How many women take it in the UK?".
19. Taylor T, Keyse L, Bryant A (2006). Contraception and Sexual Health, 2005/06 (PDF). London: Office for National Statistics. ISBN 978-1-85774-638-9. Archived from the original (PDF) on 2007-01-09. British women aged 16–49: 24% currently use the pill (17% use Combined pill, 5% use Minipill, 2% don't know type)
20. Yoshida H, Sakamoto H, Leslie A, Takahashi O, Tsuboi S, Kitamura K (June 2016). "Contraception in Japan: Current trends". Contraception. 93 (6): 475–477. doi:10.1016/j.contraception.2016.02.006. PMID 26872717.
21. World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
22. Harris G (2010-05-03). "The Pill Started More Than One Revolution". The New York Times. Retrieved 2015-09-21.
23. Hatcher RA, Trussell J, Nelson A, Cates W, Kowal D, Policar M, eds. (2011). "Combined oral contraceptives (COCs)". Contraceptive technology (20th revised ed.). New York: Ardent Media. pp. 249–341. ISBN 978-1-59708-004-0. ISSN 0091-9721. OCLC 781956734. pp. 257–258:

    Mechanism of action
    COCs prevent fertilization and, therefore, qualify as contraceptives. There is no significant evidence that they work after fertilization. The progestins in all COCs provide most of the contraceptive effect by suppressing ovulation and thickening cervical mucus, although the estrogens also make a small contribution to ovulation suppression. Cycle control is enhanced by the estrogen.
    Because COCs so effectively suppress ovulation and block ascent of sperm into the upper genital tract, the potential impact on endometrial receptivity to implantation is almost academic. When the two primary mechanisms fail, the fact that pregnancy occurs despite the endometrial changes demonstrates that those endometrial changes do not significantly contribute to the pill's mechanism of action.

24. Speroff L, Darney PD (2011). "Oral contraception". A clinical guide for contraception (5th ed.). Philadelphia: Lippincott Williams & Wilkins. pp. 19–152. ISBN 978-1-60831-610-6.
25. Levin ER, Hammes SR (2011). "Estrogens and progestins". In Goodman LS, Brunton LL, Chabner BA, Knollmann BC (eds.). Goodman & Gilman's pharmacological basis of therapeutics (12th ed.). New York: McGraw-Hill Medical. pp. 1163–1194. ISBN 978-0-07-162442-8.
26. Glasier A (2010). "Contraception". In Jameson JL, De Groot LJ (eds.). Endocrinology (6th ed.). Philadelphia: Saunders Elsevier. pp. 2417–2427. ISBN 978-1-4160-5583-9.
27. Barbieri, Robert L. (2014), Rosenwaks, Zev; Wassarman, Paul M. (eds.), "The Endocrinology of the Menstrual Cycle", Human Fertility: Methods and Protocols, Methods in Molecular Biology, New York, NY: Springer, vol. 1154, pp. 145–169, doi:10.1007/978-1-4939-0659-8_7, ISBN 978-1-4939-0659-8, PMID 24782009, retrieved 2022-09-15
28. Nelson AL, Cwiak C (2011). "Combined oral contraceptives". In Hatcher RA, Trussell J, Nelson A, Cates W, Kowal D, Policar M (eds.). Contraceptive technology (20th revised ed.). New York: Ardent Media. pp. 253–254. ISBN 978-1-59708-004-0. ISSN 0091-9721. OCLC 781956734.

    Ten different progestins have been used in the COCs that have been sold in the United States. Several different classification systems for the progestins exist, but the one most commonly used system recapitulates the history of the pill in the United States by categorizing the progestins into the so-called "generations of progestins." The first three generations of progestins are derived from 19-nortestosterone. The fourth generation is drospirenone. Newer progestins are hybrids.
    First-generation progestins. First-generation progestins include noretynodrel, norethisterone, norethisterone acetate, and etynodiol diacetate… These compounds have the lowest potency and relatively short half-lives. The short half-life did not matter in the early, high-dose pills but as doses of progestin were decreased in the more modern pills, problems with unscheduled spotting and bleeding became more common.
    Second-generation progestins. To solve the problem of unscheduled bleeding and spotting, the second generation progestins (norgestrol and levonorgestrel) were designed to be significantly more potent and to have longer half-lives than norethisterone-related progestins ... The second-generation progestins have been associated with more androgen-related side-effects such as adverse effect on lipids, oily skin, acne, and facial hair growth.
    Third-generation progestins. Third-generation progestins (desogestrel, norgestimate and elsewhere, gestodene) were introduced to maintain the potent progestational activity of second-generation progestins, but to reduce androgeneic side effects. Reduction in androgen impacts allows a fuller expression of the pill's estrogen impacts. This has some clinical benefits… On the other hand, concern arose that the increased expression of estrogen might increase the risk of venous thromboembolism (VTE). This concern introduced a pill scare in Europe until international studies were completed and correctly interpreted.
    Fourth-generation progestins. Drospirenone is an analogue of spironolactone, a potassium-sparing diuretic used to treat hypertension. Drospirenone possesses anti-mineralocorticoid and anti-androgenic properties. These properties have led to new contraceptive applications, such as treatment of premenstrual dysphoric disorder and acne… In the wake of concerns around possible increased VTE risk with less androgenic third-generation formulations, those issues were anticipated with drospirenone. They were clearly answered by large international studies.
    Next-generation progestins. More recently, newer progestins have been developed with properties that are shared with different generations of progestins. They have more profound, diverse, and discrete effects on the endometrium than prior progestins. This class would include dienogest (United States) and nomegestrol (Europe).

29. Speroff L, Darney PD (2011). "Oral contraception". A clinical guide for contraception (5th ed.). Philadelphia: Lippincott Williams & Wilkins. p. 40. ISBN 978-1-60831-610-6.
30. "How to Use Birth Control Pills | Follow Easy Instructions". www.plannedparenthood.org. Retrieved 2017-11-29.
31. Callahan TL, Caughey AB (2013). Blueprints obstetrics & gynecology (6th ed.). Baltimore, MD: Lippincott Williams & Wilkins. ISBN 9781451117028. OCLC 800907400.
32. "Birth Control Pills All Guides". October 2014.
33. World Health Organization (2016). Selected practice recommendations for contraceptive use (Third ed.). Geneva: World Health Organization. p. 150. hdl:10665/252267. ISBN 9789241565400. OCLC 985676200.
34. Curtis KM, Tepper NK, Jatlaoui TC, Berry-Bibee E, Horton LG, Zapata LB, et al. (July 2016). "U.S. Medical Eligibility Criteria for Contraceptive Use, 2016". MMWR. Recommendations and Reports. 65 (3): 1–103. doi:10.15585/mmwr.rr6503a1. PMID 27467196.
35. Trussell J (April 2009). "Understanding contraceptive failure". Best Practice & Research. Clinical Obstetrics & Gynaecology. Contraception and Sexual Health. 23 (2): 199–209. doi:10.1016/j.bpobgyn.2008.11.008. PMC 3638203. PMID 19223239.
36. Trussell J (May 2011). "Contraceptive failure in the United States". Contraception. 83 (5): 397–404. doi:10.1016/j.contraception.2011.01.021. PMC 3638209. PMID 21477680.
37. Speroff L, Darney PD (2005). "Oral Contraception". A Clinical Guide for Contraception (4th ed.). Philadelphia: Lippincott Williams & Wilkins. pp. 21–138. ISBN 978-0-7817-6488-9.
38. FFPRHC (2007). (PDF). Archived from the original (PDF) on 2007-07-04. Retrieved 2007-06-26.
39. Edelman A, Micks E, Gallo MF, Jensen JT, Grimes DA (July 2014). "Continuous or extended cycle vs. cyclic use of combined hormonal contraceptives for contraception". The Cochrane Database of Systematic Reviews. 2014 (7): CD004695. doi:10.1002/14651858.CD004695.pub3. PMC 6837850. PMID 25072731.
40. Curtis KM, Jatlaoui TC, Tepper NK, Zapata LB, Horton LG, Jamieson DJ, Whiteman MK (July 2016). "U.S. Selected Practice Recommendations for Contraceptive Use, 2016". MMWR. Recommendations and Reports. 65 (4): 1–66. doi:10.15585/mmwr.rr6504a1. PMID 27467319.
41. "Last Week of Birth Control Pills". 21 March 2016.
42. Gladwell M (2000-03-10). . The New Yorker. Archived from the original on 11 May 2013. Retrieved 2009-02-04.
43. Mayo Clinic staff. "Birth control pill FAQ: Benefits, risks and choices". Mayo Clinic. Retrieved 1 February 2013.
44. . PatentStorm LLC. Archived from the original on June 13, 2011. Retrieved 2010-11-19.
45. Hercberg S, Preziosi P, Galan P (April 2001). "Iron deficiency in Europe". Public Health Nutrition. 4 (2B): 537–545. doi:10.1079/phn2001139. PMID 11683548.
46. Viswanathan M, Treiman KA, Kish-Doto J, Middleton JC, Coker-Schwimmer EJ, Nicholson WK (January 2017). "Folic Acid Supplementation for the Prevention of Neural Tube Defects: An Updated Evidence Report and Systematic Review for the US Preventive Services Task Force". JAMA. 317 (2): 190–203. doi:10.1001/jama.2016.19193. PMID 28097361.
47. Lassi ZS, Bhutta ZA (April 2012). "Clinical utility of folate-containing oral contraceptives". International Journal of Women's Health. 4: 185–190. doi:10.2147/IJWH.S18611. PMC 3346209. PMID 22570577.
48. FDA (2003-09-25). . Food and Drug Administration. Archived from the original on 2006-10-07. Retrieved 2006-11-09.
49. CYWH Staff (2011-10-18). . Archived from the original on 2013-02-05. Retrieved 1 February 2013.
50. "Information for Consumers (Drugs) - Find Information about a Drug". www.fda.gov. Retrieved 2017-12-13.
51. "UpToDate". www.uptodate.com. Retrieved 2022-09-15.
52. Dumesic, Daniel A.; Lobo, Rogerio A. (August 2013). "Cancer risk and PCOS". Steroids. 78 (8): 782–785. doi:10.1016/j.steroids.2013.04.004. ISSN 1878-5867. PMID 23624028. S2CID 10185317.
53. "Polycystic Ovary Syndrome (PCOS)". www.acog.org. Retrieved 2022-09-15.
54. Barakat RR, Park RC, Grigsby PW, et al. Corpus: Epithelial Tumors. In: Principles and Practice of Gynecologic Oncology, 2nd, Hoskins WH, Perez CA, Young RC (Eds), Lippincott-Raven Publishers, Philadelphia 1997. p.859
55. Hardiman P, Pillay OC, Atiomo W (May 2003). "Polycystic ovary syndrome and endometrial carcinoma". Lancet. 361 (9371): 1810–2. doi:10.1016/s0140-6736(03)13409-5. PMID 12781553. S2CID 27453081.
56. "Does Birth Control Help with Symptoms of PCOS?". Healthline. 2022-08-09. Retrieved 2022-09-18.
57. "Can birth control pills cure PCOS". www.acog.org. Retrieved 2022-09-18.
58. Huber J, Walch K (January 2006). "Treating acne with oral contraceptives: use of lower doses". Contraception. 73 (1): 23–9. doi:10.1016/j.contraception.2005.07.010. PMID 16371290.
59. "Hormonal Contraceptives and Acne: A Retrospective Analysis of 2147 Patients". JDDonline - Journal of Drugs in Dermatology. Retrieved 2022-09-15.
60. "Birth Control for Acne: Brands to Try, How It Works, and More". Healthline. 2022-08-26. Retrieved 2022-09-15.
61. Chang L. "Birth Control of Acne". WebMD, LLC. Retrieved 1 February 2013.
62. "DailyMed - ORTHO TRI CYCLEN- norgestimate and ethinyl estradiol ORTHO CYCLEN- norgestimate and ethinyl estradiol". dailymed.nlm.nih.gov. Retrieved 2017-12-13.
63. "Beyaz Package Insert" (PDF). FDA.
64. "UpToDate". www.uptodate.com. Retrieved 2022-09-18.
65. "Hirsutism: What It Is, In Women, Causes, PCOS & Treatment". Cleveland Clinic. Retrieved 2022-09-18.
66. "ACOG Endometriosis FAQ".
67. Zorbas KA, Economopoulos KP, Vlahos NF (July 2015). "Continuous versus cyclic oral contraceptives for the treatment of endometriosis: a systematic review". Archives of Gynecology and Obstetrics. 292 (1): 37–43. doi:10.1007/s00404-015-3641-1. PMID 25644508. S2CID 23340983.
68. "Heavy Menstrual Bleeding". www.acog.org. Retrieved 2022-09-18.
69. Apgar, Barbara S.; Kaufman, Amanda H.; George-Nwogu, Uche; Kittendorf, Anne (2007-06-15). "Treatment of Menorrhagia". American Family Physician. 75 (12): 1813–1819. PMID 17619523.
70. "UpToDate". www.uptodate.com. Retrieved 2022-09-15.
71. "Noncontraceptive Benefits of Birth Control Pills". www.reproductivefacts.org. Retrieved 2022-09-15.
72. American Medical Society for Sports Medicine (24 April 2014), "Five Things Physicians and Patients Should Question", Choosing Wisely: an initiative of the ABIM Foundation, American Medical Society for Sports Medicine, retrieved 29 July 2014
73. Black A, Guilbert E, Costescu D, Dunn S, Fisher W, Kives S, et al. (April 2017). "No. 329-Canadian Contraception Consensus Part 4 of 4 Chapter 9: Combined Hormonal Contraception". Journal of Obstetrics and Gynaecology Canada. 39 (4): 229–268.e5. doi:10.1016/j.jogc.2016.10.005. PMID 28413042.
74. Cooper DB, Patel P, Mahdy H (2019). "Oral Contraceptive Pills". StatPearls. StatPearls Publishing. PMID 28613632. Retrieved 2019-08-05.
75. "Can Any Woman Take Birth Control Pills?". WebMD. Retrieved 8 May 2016.
76. Medical eligibility criteria for contraceptive use (Fifth ed.). Geneva, Switzerland: Reproductive Health and Research, World Health Organization. 2015. ISBN 978-92-4-154915-8. OCLC 932048744.
77. Lopez LM, Grey TW, Stuebe AM, Chen M, Truitt ST, Gallo MF, et al. (Cochrane Fertility Regulation Group) (March 2015). "Combined hormonal versus nonhormonal versus progestin-only contraception in lactation". The Cochrane Database of Systematic Reviews (3): CD003988. doi:10.1002/14651858.CD003988.pub2. PMID 25793657.
78. "Classifications for Combined Hormonal Contraceptives | CDC". www.cdc.gov. 2020-04-09. Retrieved 2020-12-07.
79. Curtis, Kathryn M. (2016). "U.S. Medical Eligibility Criteria for Contraceptive Use, 2016". MMWR. Recommendations and Reports. 65 (3): 1–103. doi:10.15585/mmwr.rr6503a1. ISSN 1057-5987. PMID 27467196.
80. "Is There a Link Between Birth Control Pills and Higher Breast Cancer Risk?". www.breastcancer.org. Retrieved 2022-09-18.
81. Pernambuco-Holsten, Christina. "Birth Control and Cancer Risk: 6 Things You Should Know | Memorial Sloan Kettering Cancer Center". www.mskcc.org. Retrieved 2022-09-18.
82. "What are the best birth control options that aren't hormonal?". www.plannedparenthood.org. Retrieved 2022-09-18.
83. "Do Hormonal Contraceptives Increase Breast Cancer Risk?". www.breastcancer.org. Retrieved 2022-09-18.
84. Crooks RL, Baur K (2005). Our Sexuality. Belmont, CA: Thomson Wadsworth. ISBN 978-0-534-65176-3.^{[page needed]}
85. "Appendix 10: Myths about contraception". . WHO. 2005. Archived from the original on 2007-01-07. Retrieved 2022-09-14.{{cite book}}: CS1 maint: bot: original URL status unknown (link)
86. Holck S. "Contraceptive Safety". Special Challenges in Third World Women's Health. 1989 Annual Meeting of the American Public Health Association. Retrieved 2006-10-07.
87. Serfaty D (October 1992). "Medical aspects of oral contraceptive discontinuation". Advances in Contraception. 8 (Suppl 1): 21–33. doi:10.1007/bf01849448. PMID 1442247. S2CID 11876371.
88. Sanders SA, Graham CA, Bass JL, Bancroft J (July 2001). "A prospective study of the effects of oral contraceptives on sexuality and well-being and their relationship to discontinuation". Contraception. 64 (1): 51–8. doi:10.1016/S0010-7824(01)00218-9. PMID 11535214.
89. Yolton DP, Yolton RL, López R, Bogner B, Stevens R, Rao D (November 1994). "The effects of gender and birth control pill use on spontaneous blink rates". Journal of the American Optometric Association. 65 (11): 763–70. PMID 7822673.
90. Huber JC, Bentz EK, Ott J, Tempfer CB (September 2008). "Non-contraceptive benefits of oral contraceptives". Expert Opinion on Pharmacotherapy. 9 (13): 2317–2325. doi:10.1517/14656566.9.13.2317. PMID 18710356. S2CID 73326364.
91. Nelson RJ (2005). An introduction to behavioral endocrinology (3rd ed.). Sunderland, Mass: Sinauer Associates. ISBN 978-0-87893-617-5.^{[page needed]}
92. Vo C, Carney ME (December 2007). "Ovarian cancer hormonal and environmental risk effect". Obstetrics and Gynecology Clinics of North America. 34 (4): 687–700, viii. doi:10.1016/j.ogc.2007.09.008. PMID 18061864.
93. Bandera CA (June 2005). "Advances in the understanding of risk factors for ovarian cancer". The Journal of Reproductive Medicine. 50 (6): 399–406. PMID 16050564.
94. Pragout D, Laurence V, Baffet H, Raccah-Tebeka B, Rousset-Jablonski C (December 2018). "Contraception et cancer. RPC Contraception CNGOF" [Contraception and cancer: CNGOF Contraception Guidelines]. Gynécologie Obstétrique Fertilité & Sénologie. 46 (12): 834–844. doi:10.1016/j.gofs.2018.10.010. PMID 30385358. S2CID 196536513.
95. Wanyonyi, Sikolia Z.; Stones, William R.; Sequeira, Evan (2011). "Health-related quality of life changes among users of depot medroxyprogesterone acetate for contraception". Contraception. 84 (5): e17–e22. doi:10.1016/j.contraception.2011.05.022. PMID 22018133.
96. "Apri oral : Uses, Side Effects, Interactions, Pictures, Warnings & Dosing".
97. Blanco-Molina A, Monreal M (February 2010). "Venous thromboembolism in women taking hormonal contraceptives". Expert Review of Cardiovascular Therapy. 8 (2): 211–5. doi:10.1586/erc.09.175. PMID 20136607. S2CID 41309800.
98. Roach RE, Helmerhorst FM, Lijfering WM, Stijnen T, Algra A, Dekkers OM (August 2015). "Combined oral contraceptives: the risk of myocardial infarction and ischemic stroke". The Cochrane Database of Systematic Reviews. 8 (8): CD011054. doi:10.1002/14651858.CD011054.pub2. PMC 6494192. PMID 26310586.
99. Rang HP, Dale MM, Ritter JM, Flower RJ, Henderson G (2012). "The reproductive system". Rang and Dale's pharmacology (7th ed.). Edinburgh: Elsevier/Churchill Livingstone. p. 426. ISBN 978-0-7020-3471-8.
100. ESHRE Capri Workshop Group (2013). "Venous thromboembolism in women: a specific reproductive health risk". Human Reproduction Update. 19 (5): 471–82. doi:10.1093/humupd/dmt028. PMID 23825156.
101. Lidegaard Ø, Milsom I, Geirsson RT, Skjeldestad FE (July 2012). "Hormonal contraception and venous thromboembolism". Acta Obstetricia et Gynecologica Scandinavica. 91 (7): 769–78. doi:10.1111/j.1600-0412.2012.01444.x. PMID 22568831. S2CID 2691199.
102. Dunn N (April 2011). "The risk of deep venous thrombosis with oral contraceptives containing drospirenone". BMJ. 342: d2519. doi:10.1136/bmj.d2519. PMID 21511807. S2CID 42721801.
103. "Highlights of Prescribing Information for Yasmin" (PDF). FDA.
104. Amoozegar F, Ronksley PE, Sauve R, Menon BK (2015). "Hormonal contraceptives and cerebral venous thrombosis risk: a systematic review and meta-analysis". Front Neurol. 6: 7. doi:10.3389/fneur.2015.00007. PMC 4313700. PMID 25699010.
105. Bast RC, Brewer M, Zou C, Hernandez MA, Daley M, Ozols R, Lu K, Lu Z, Badgwell D, Mills GB, Skates S, Zhang Z, Chan D, Lokshin A, Yu Y (2007). "Prevention and early detection of ovarian cancer: mission impossible?". Cancer Prevention. Recent Results Cancer Res. Recent Results in Cancer Research. Vol. 174. pp. 91–100. doi:10.1007/978-3-540-37696-5_9. ISBN 978-3-540-37695-8. PMID 17302189.
106. Vessey M, Yeates D, Flynn S (September 2010). "Factors affecting mortality in a large cohort study with special reference to oral contraceptive use". Contraception. 82 (3): 221–9. doi:10.1016/j.contraception.2010.04.006. PMID 20705149.
107. Nappi, Rossella E.; Pellegrinelli, Alice; Campolo, Federica; Lanzo, Gabriele; Santamaria, Valentina; Suragna, Alessandro; Spinillo, Arsenio; Benedetto, Chiara (2015-01-02). "Effects of combined hormonal contraception on health and wellbeing: Women's knowledge in northern Italy". The European Journal of Contraception & Reproductive Health Care. 20 (1): 36–46. doi:10.3109/13625187.2014.961598. ISSN 1362-5187. PMID 25317952. S2CID 26048792.
108. Cibula D, Gompel A, Mueck AO, La Vecchia C, Hannaford PC, Skouby SO, Zikan M, Dusek L (2010). "Hormonal contraception and risk of cancer". Human Reproduction Update. 16 (6): 631–50. doi:10.1093/humupd/dmq022. PMID 20543200.
109. Gierisch JM, Coeytaux RR, Urrutia RP, Havrilesky LJ, Moorman PG, Lowery WJ, Dinan M, McBroom AJ, Hasselblad V, Sanders GD, Myers ER (November 2013). "Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review". Cancer Epidemiology, Biomarkers & Prevention. 22 (11): 1931–43. doi:10.1158/1055-9965.EPI-13-0298. PMID 24014598.
110. Anothaisintawee T, Wiratkapun C, Lerdsitthichai P, Kasamesup V, Wongwaisayawan S, Srinakarin J, Hirunpat S, Woodtichartpreecha P, Boonlikit S, Teerawattananon Y, Thakkinstian A (September 2013). "Risk factors of breast cancer: a systematic review and meta-analysis". Asia-Pacific Journal of Public Health. 25 (5): 368–87. doi:10.1177/1010539513488795. PMID 23709491. S2CID 206616972.
111. Zhu H, Lei X, Feng J, Wang Y (December 2012). "Oral contraceptive use and risk of breast cancer: a meta-analysis of prospective cohort studies". The European Journal of Contraception & Reproductive Health Care. 17 (6): 402–14. doi:10.3109/13625187.2012.715357. PMID 23061743. S2CID 33708638.
112. Mørch, LS; Skovlund, CW; Hannaford, PC; Iversen, L; Fielding, S; Lidegaard, Ø (7 December 2017). "Contemporary Hormonal Contraception and the Risk of Breast Cancer". The New England Journal of Medicine. 377 (23): 2228–2239. doi:10.1056/NEJMoa1700732. hdl:2164/15157. PMID 29211679. S2CID 4498610.
113. Lopez, Laureen M.; Ramesh, Shanthi; Chen, Mario; Edelman, Alison; Otterness, Conrad; Trussell, James; Helmerhorst, Frans M. (2016-08-28). "Progestin-only contraceptives: effects on weight". The Cochrane Database of Systematic Reviews. 2016 (8): CD008815. doi:10.1002/14651858.CD008815.pub4. ISSN 1469-493X. PMC 5034734. PMID 27567593.
114. Lopez LM, Edelman A, Chen M, Otterness C, Trussell J, Helmerhorst FM (July 2013). Lopez LM (ed.). "Progestin-only contraceptives: effects on weight". The Cochrane Database of Systematic Reviews. 7 (7): CD008815. doi:10.1002/14651858.CD008815.pub3. PMC 3855691. PMID 23821307.
115. Hatcher RD, Nelson AL (2004). "Combined Hormonal Contraceptive Methods". In Hatcher RD (ed.). Contraceptive technology (18th ed.). New York: Ardent Media, Inc. pp. 403, 432, 434. ISBN 978-0-9664902-5-1.
116. Speroff L (2005). A clinical guide for contraception (4th ed.). Hagerstown, MD: Lippincott Williams & Wilkins. p. 72. ISBN 978-0-7817-6488-9.
117. Weir GC, DeGroot LJ, Grossman A, Marshall JF, Melmed S, Potts JT (2006). Endocrinology (5th ed.). St. Louis, Mo: Elsevier Saunders. p. 2999. ISBN 978-0-7216-0376-6.^{[page needed]}
118. Westhoff CL, Heartwell S, Edwards S, Zieman M, Stuart G, Cwiak C, Davis A, Robilotto T, Cushman L, Kalmuss D (April 2007). "Oral contraceptive discontinuation: do side effects matter?". American Journal of Obstetrics and Gynecology. 196 (4): 412.e1–6, discussion 412.e6–7. doi:10.1016/j.ajog.2006.12.015. PMC 1903378. PMID 17403440.
119. Seal BN, Brotto LA, Gorzalka BB (August 2005). "Oral contraceptive use and female genital arousal: methodological considerations". Journal of Sex Research. 42 (3): 249–58. doi:10.1080/00224490509552279. PMID 19817038. S2CID 10402534.
120. Higgins JA, Davis AR (July 2014). "Contraceptive sex acceptability: a commentary, synopsis and agenda for future research". Contraception. 90 (1): 4–10. doi:10.1016/j.contraception.2014.02.029. PMC 4247241. PMID 24792147.
121. Burrows LJ, Basha M, Goldstein AT (2012). "The Effects of Hormonal Contraceptives on Female Sexuality: A Review". The Journal of Sexual Medicine. Elsevier. 9 (9): 2213–2223. doi:10.1111/j.1743-6109.2012.02848.x. PMID 22788250.
122. Pastor Z, Holla K, Chmel R (2013). "The influence of combined oral contraceptives on female sexual desire: a systematic review". The European Journal of Contraception & Reproductive Health Care. Taylor & Francis. 18 (1): 27–43. doi:10.3109/13625187.2012.728643. PMID 23320933. S2CID 34748865.
123. Boudesseul J, Gildersleeve KA, Haselton MG, Bègue L (2019). "Do women expose themselves to more health-related risks in certain phases of the menstrual cycle? A meta-analytic review". Neuroscience & Biobehavioral Reviews. Elsevier. 107: 505–524. doi:10.1016/j.neubiorev.2019.08.016. PMID 31513819.
124. Panzer C, Wise S, Fantini G, Kang D, Munarriz R, Guay A, Goldstein I (January 2006). "Impact of oral contraceptives on sex hormone-binding globulin and androgen levels: a retrospective study in women with sexual dysfunction". The Journal of Sexual Medicine. 3 (1): 104–13. doi:10.1111/j.1743-6109.2005.00198.x. PMID 16409223.
     Description of the study results in Medical News Today: . January 4, 2006. Archived from the original on April 24, 2011. Retrieved April 9, 2011.
125. Panzer C, Wise S, Fantini G, Kang D, Munarriz R, Guay A, Goldstein I (January 2006). "Impact of oral contraceptives on sex hormone-binding globulin and androgen levels: a retrospective study in women with sexual dysfunction". The Journal of Sexual Medicine. 3 (1): 104–13. doi:10.1111/j.1743-6109.2005.00198.x. PMID 16409223.
126. Zheng J, Islam RM, Skiba MA, Bell RJ, Davis SR (2020). "Associations between androgens and sexual function in premenopausal women: a cross-sectional study". The Lancet Diabetes & Endocrinology. Elsevier. 8 (8): 693–702. doi:10.1016/S2213-8587(20)30239-4.
127. Roberts SC, Havlicek J, Flegr J, Hruskova M, Little AC, Jones BC, Perrett DI, Petrie M (2004). "Female facial attractiveness increases during the fertile phase of the menstrual cycle" (PDF). Proceedings of the Royal Society B: Biological Sciences. Royal Society. 271 (Supplemental 5): S270–S272. doi:10.1098/rsbl.2004.0174. PMC 1810066. PMID 15503991.
128. Miller GF, Tybur JM, Jordan BD (2007). "Ovulatory cycle effects on tip earnings by lap dancers: economic evidence for human estrus?" (PDF). Evolution and Human Behavior. 28 (6): 375–381. CiteSeerX 10.1.1.154.8176. doi:10.1016/j.evolhumbehav.2007.06.002.
129. Pipitone RN, Gallup GG (2008). "Women's voice attractiveness varies across the menstrual cycle". Evolution and Human Behavior. Elsevier. 29 (4): 268–274. doi:10.1016/j.evolhumbehav.2008.02.001.
130. Chavanne TJ, Gallup GG (1998). "Variation in Risk Taking Behavior Among Female College Students as a Function of the Menstrual Cycle". Evolution and Human Behavior. Elsevier. 19 (1): 27–32. doi:10.1016/S1090-5138(98)00016-6.
131. Buss DM (2016) [1994]. The Evolution of Desire: Strategies of Human Mating (3rd ed.). New York: Basic Books. pp. 260–262. ISBN 978-0465097760.
132. Bröder A, Hohmann N (2003). "Variations in risk taking behavior over the menstrual cycle: An improved replication". Evolution and Human Behavior. Elsevier. 24 (6): 391–398. doi:10.1016/S1090-5138(03)00055-2.
133. Burns BD (2006). "Cognitive Neuroendocrinology: Risk Preference Changes Across the Menstrual Cycle". Proceedings of the Annual Meeting of the Cognitive Science Society. 28: 125–130. ISSN 1069-7977. Retrieved April 27, 2023.
134. Kulkarni J (July 2007). "Depression as a side effect of the contraceptive pill". Expert Opinion on Drug Safety. 6 (4): 371–4. doi:10.1517/14740338.6.4.371. PMID 17688380. S2CID 8836005.
135. Skovlund CW, Mørch LS, Kessing LV, Lidegaard Ø (November 2016). "Association of Hormonal Contraception With Depression". JAMA Psychiatry. 73 (11): 1154–1162. doi:10.1001/jamapsychiatry.2016.2387. PMID 27680324.
136. Zettermark S, Perez Vicente R, Merlo J (2018-03-22). "Hormonal contraception increases the risk of psychotropic drug use in adolescent girls but not in adults: A pharmacoepidemiological study on 800 000 Swedish women". PLOS ONE. 13 (3): e0194773. Bibcode:2018PLoSO..1394773Z. doi:10.1371/journal.pone.0194773. PMC 5864056. PMID 29566064.
137. Burnett-Watson K (October 2005). . Archived from the original on 2007-03-20. Retrieved 2007-03-20., which cites:

     Kulkarni J, Liew J, Garland KA (November 2005). "Depression associated with combined oral contraceptives--a pilot study". Australian Family Physician. 34 (11): 990. PMID 16299641.

138. Young EA, Kornstein SG, Harvey AT, Wisniewski SR, Barkin J, Fava M, Trivedi MH, Rush AJ (August 2007). "Influences of hormone-based contraception on depressive symptoms in premenopausal women with major depression". Psychoneuroendocrinology. 32 (7): 843–53. doi:10.1016/j.psyneuen.2007.05.013. PMC 2100423. PMID 17629629.
139. ACOG Committee on Practice Bulletins-Gynecology (2006). "ACOG Practice Bulletin No. 73: Use of Hormonal Contraception in Women with Coexisting Medical Conditions". Obstetrics & Gynecology. 107 (6): 1453–72. doi:10.1097/00006250-200606000-00055. PMID 16738183.
140. World Health Organization (2004). "Low-dose combined oral contraceptives". Medical Eligibility Criteria for Contraceptive Use (third ed.). Geneva: Low-dose combined oral contraceptives. hdl:10665/42907. ISBN 978-92-4-156266-9.^{[page needed]}
141. FFPRHC (2006). (PDF). Archived from the original (PDF) on 2007-06-19. Retrieved 2007-03-31.
142. Cilia La Corte AL, Carter AM, Turner AJ, Grant PJ, Hooper NM (December 2008). "The bradykinin-degrading aminopeptidase P is increased in women taking the oral contraceptive pill". Journal of the Renin-Angiotensin-Aldosterone System. 9 (4): 221–5. doi:10.1177/1470320308096405. PMID 19126663. S2CID 206729914.
143. . NDDIC. July 2007. Archived from the original on 2010-08-11. Retrieved 2010-08-13.
144. Raloff J (2013-09-23). "Birth control pills can limit muscle-training gains". Science News. Retrieved 2018-10-22.
145. "Love woes can be blamed on contraceptive pill: research – ABC News (Australian Broadcasting Corporation)". ABC News. Abc.net.au. 2008-08-14. Retrieved 2010-03-20.
146. Kollndorfer K, Ohrenberger I, Schöpf V (2016). "Contraceptive Use Affects Overall Olfactory Performance: Investigation of Estradiol Dosage and Duration of Intake". PLOS ONE. 11 (12): e0167520. Bibcode:2016PLoSO..1167520K. doi:10.1371/journal.pone.0167520. PMC 5176159. PMID 28002464.
147. Roberts SC, Gosling LM, Carter V, Petrie M (December 2008). "MHC-correlated odour preferences in humans and the use of oral contraceptives". Proceedings. Biological Sciences. 275 (1652): 2715–22. doi:10.1098/rspb.2008.0825. PMC 2605820. PMID 18700206.
148. Vercellini P, Eskenazi B, Consonni D, Somigliana E, Parazzini F, Abbiati A, Fedele L (2010). "Oral contraceptives and risk of endometriosis: a systematic review and meta-analysis". Human Reproduction Update. 17 (2): 159–70. doi:10.1093/humupd/dmq042. PMID 20833638.
149. Zimmerman Y, Eijkemans MJ, Coelingh Bennink HJ, Blankenstein MA, Fauser BC (2013). "The effect of combined oral contraception on testosterone levels in healthy women: a systematic review and meta-analysis". Human Reproduction Update. 20 (1): 76–105. doi:10.1093/humupd/dmt038. PMC 3845679. PMID 24082040.
150. Scholes D, Hubbard RA, Ichikawa LE, LaCroix AZ, Spangler L, Beasley JM, Reed S, Ott SM (September 2011). "Oral contraceptive use and bone density change in adolescent and young adult women: a prospective study of age, hormone dose, and discontinuation". The Journal of Clinical Endocrinology and Metabolism. 96 (9): E1380–7. doi:10.1210/jc.2010-3027. PMC 3167673. PMID 21752879.
151. The effects of broad-spectrum antibiotics on Combined contraceptive pills is not found on systematic interaction metanalysis (Archer, 2002), although "individual patients do show large decreases in the plasma concentrations of ethinylestradiol when they take certain other antibiotics" (Dickinson, 2001). "experts on this topic still recommend informing oral contraceptive users of the potential for a rare interaction" (DeRossi, 2002) and this remains current (2006) UK Family Planning Association advice 2007-02-08 at the Wayback Machine.
152. Archer JS, Archer DF (June 2002). "Oral contraceptive efficacy and antibiotic interaction: a myth debunked". Journal of the American Academy of Dermatology. 46 (6): 917–23. doi:10.1067/mjd.2002.120448. PMID 12063491.
153. Dickinson BD, Altman RD, Nielsen NH, Sterling ML (November 2001). "Drug interactions between oral contraceptives and antibiotics". Obstetrics and Gynecology. 98 (5 Pt 1): 853–60. doi:10.1016/S0029-7844(01)01532-0. PMID 11704183. S2CID 41354899.
154. DeRossi SS, Hersh EV (October 2002). "Antibiotics and oral contraceptives". Dental Clinics of North America. 46 (4): 653–64. CiteSeerX 10.1.1.620.9933. doi:10.1016/S0011-8532(02)00017-4. PMID 12436822.
155. Berry-Bibee EN, Kim MJ, Tepper NK, Riley HE, Curtis KM (December 2016). "Co-administration of St. John's wort and hormonal contraceptives: a systematic review". Contraception. 94 (6): 668–677. doi:10.1016/j.contraception.2016.07.010. PMID 27444983.
156. Marks L (2001). Sexual Chemistry: A History of the Contraceptive Pill. Yale University Press. pp. 73–75, 77–78. ISBN 978-0-300-08943-1.
157. Gelijns A (1991). Innovation in Clinical Practice: The Dynamics of Medical Technology Development. National Academies. pp. 167–. NAP:13513.
158. Blum RW (22 October 2013). Adolescent Health Care: Clinical Issues. Elsevier Science. pp. 216–. ISBN 978-1-4832-7738-7.
159. Tone A, Watkins ES (8 January 2007). Medicating Modern America: Prescription Drugs in History. NYU Press. pp. 117–119. ISBN 978-0-8147-8301-6.
160. McGuire JL (2000). Pharmaceuticals, 4 Volume Set. Wiley. p. 1580,1599. ISBN 978-3-527-29874-7.
161. Rao B (1 January 1998). Clinical Gynecology (4th ed.). Orient Blackswan. pp. 163–. ISBN 978-81-250-1622-9.
162. Labhart A (6 December 2012). Clinical Endocrinology: Theory and Practice. Springer Science & Business Media. pp. 571–. ISBN 978-3-642-96158-8.
163. Goldzieher JW, Rudel HW (October 1974). "How the oral contraceptives came to be developed". JAMA. 230 (3): 421–5. doi:10.1001/jama.230.3.421. PMID 4606623.
164. Goldzieher JW (May 1982). "Estrogens in oral contraceptives: historical perspectives". The Johns Hopkins Medical Journal. 150 (5): 165–9. PMID 7043034.
165. Perone N (Spring 1993). "The history of steroidal contraceptive development: the progestins". Perspectives in Biology and Medicine. 36 (3): 347–62. doi:10.1353/pbm.1993.0054. PMID 8506121. S2CID 46312750.
166. Goldzieher JW (Spring 1993). "The history of steroidal contraceptive development: the estrogens". Perspectives in Biology and Medicine. 36 (3): 363–8. doi:10.1353/pbm.1993.0066. PMID 8506122. S2CID 28975213.
167. Maisel AQ (1965). The Hormone Quest. New York: Random House. OCLC 543168.
168. Asbell B (1995). The Pill: A Biography of the Drug That Changed the World. New York: Random House. ISBN 978-0-679-43555-6.
169. Lehmann PA, Bolivar A, Quintero R (March 1973). "Russell E. Marker. Pioneer of the Mexican steroid industry". Journal of Chemical Education. 50 (3): 195–9. Bibcode:1973JChEd..50..195L. doi:10.1021/ed050p195. PMID 4569922.
170. Vaughan P (1970). The Pill on Trial. New York: Coward-McCann. OCLC 97780.
171. Tone A (2001). Devices & Desires: A History of Contraceptives in America. New York: Hill and Wang. ISBN 978-0-8090-3817-6.
172. Pincus G, Bialy G (1964). Drugs Used in Control of Reproduction. Adv Pharmacol. Advances in Pharmacology. Vol. 3. pp. 285–313. doi:10.1016/S1054-3589(08)61115-1. ISBN 9780120329038. PMID 14232795. The original observation of Makepeace et al. (1937) that progesterone inhibited ovulation in the rabbit was substantiated by Pincus and Chang (1953). In women, 300 mg of progesterone per day taken orally resulted in ovulation inhibition in 80% of cases (Pincus, 1956). The high dosage and frequent incidence of breakthrough bleeding limited the practical application of the method. Subsequently, the utilization of potent 19-norsteroids, which could be given orally, opened the field to practical oral contraception.
173. Nance K. "Jonathan Eig on 'The Birth of the Pill'". Chicago Tribune.
174. "The Birth of the Pill". W. W. Norton & Company.
175. Manning K (17 October 2014). "Book review: 'The Birth of the Pill,' and the reinvention of sex, by Jonathan Eig" – via washingtonpost.com.
176. Reed J (1978). From Private Vice to Public Virtue: The Birth Control Movement and American Society Since 1830. New York: Basic Books. ISBN 978-0-465-02582-4.
177. Speroff L (2009). A Good Man: Gregory Goodwin Pincus: The Man, His Story, The Birth Control Pill. Portland, Oregon: Arnica. ISBN 978-0-9801942-9-6.
178. Fields A (2003). Katharine Dexter McCormick: Pioneer for Women's Rights. Westport, Conn.: Prager. ISBN 978-0-275-98004-7.
179. McLaughlin L (1982). The Pill, John Rock, and the Church: The Biography of a Revolution. Boston: Little, Brown. ISBN 978-0-316-56095-5.
180. Rock J, Garcia CR, Pincus G (1957). "Synthetic progestins in the normal human menstrual cycle". Recent Progress in Hormone Research. 13: 323–39, discussion 339–46. PMID 13477811.
181. Pincus G (December 1958). "The hormonal control of ovulation and early development". Postgraduate Medicine. 24 (6): 654–60. doi:10.1080/00325481.1958.11692305. PMID 13614060.
182. Pincus G (1959). Progestational Agents and the Control of Fertility. Vitamins & Hormones. Vol. 17. pp. 307–324. doi:10.1016/S0083-6729(08)60274-5. ISBN 9780127098173. ISSN 0083-6729. Ishikawa et al. (1957) employing the same regime of progesterone administration also observed suppression of ovulation in a proportion of the cases taken to laparotomy. Although sexual intercourse was practised freely by the subjects of our experiments and those of Ishikawa el al., no pregnancies occurred. Since ovulation presumably took place in a proportion of cycles, the lack of any pregnancies may be due to chance, but Ishikawa et al. (1957) have presented data indicating that in women receiving oral progesterone the cervical mucus becomes impenetrable to sperm.
183. Diczfalusy E (December 1965). "Probable mode of action of oral contraceptives". BMJ. 2 (5475): 1394–9. doi:10.1136/bmj.2.5475.1394. PMC 1847181. PMID 5848673. At the Fifth International Conference on Planned Parenthood in Tokyo, Pincus (1955) reported an ovulation inhibition by progesterone or norethynodrel1 taken orally by women. This report indicated the beginning of a new era in the history of contraception. ... That the cervical mucus might be one of the principal sites of action was suggested by the first studies of Pincus (1956, 1959) and of Ishikawa et al. (1957). These investigators found that no pregnancies occurred in women treated orally with large doses of progesterone, though ovulation was inhibited only in some 70% of the cases studied. ... The mechanism of protection in this method—and probably in that of Pincus (1956) and of Ishikawa et al. (1957)—must involve an effect on the cervical mucus and/or endometrium and Fallopian tubes.
184. Ramírez de Arellano AB, Seipp C (10 October 2017). Colonialism, Catholicism, and Contraception: A History of Birth Control in Puerto Rico. University of North Carolina Press. pp. 107–. ISBN 978-1-4696-4001-3. Still, neither of the two researchers was completely satisfied with the results. Progesterone tended to cause "premature menses," or breakthrough bleeding, in approximately 20 percent of the cycles, an occurrence that disturbed the patients and worried Rock.17 In addition, Pincus was concerned about the failure to inhibit ovulation in all the cases. Only large doses of orally administered progesterone could insure the suppression of ovulation, and these doses were expensive. The mass use of this regimen as a birth control method was thus seriously imperiled.
185. Chang MC (September 1978). "Development of the oral contraceptives". American Journal of Obstetrics and Gynecology. 132 (2): 217–9. doi:10.1016/0002-9378(78)90928-6. PMID 356615.
186. Garcia CR, Pincus G, Rock J (November 1956). "Effects of certain 19-nor steroids on the normal human menstrual cycle". Science. 124 (3227): 891–3. Bibcode:1956Sci...124..891R. doi:10.1126/science.124.3227.891. PMID 13380401.
187. Rock J, García CR (1957). "Observed effects of 19-nor steroids on ovulation and menstruation". Proceedings of a Symposium on 19-Nor Progestational Steroids. Chicago: Searle Research Laboratories. pp. 14–31. OCLC 935295.
188. Pincus G, Rock J, Garcia CR, Ricewray E, Paniagua M, Rodriguez I (June 1958). "Fertility control with oral medication". American Journal of Obstetrics and Gynecology. 75 (6): 1333–46. doi:10.1016/0002-9378(58)90722-1. PMID 13545267.
189. García CR (December 2004). "Development of the pill". Annals of the New York Academy of Sciences. 1038: 223–6. Bibcode:2004NYASA1038..223G. doi:10.1196/annals.1315.031. PMID 15838117. S2CID 25550745.
190. Strauss JF, Mastroianni L (January 2005). "In memoriam: Celso-Ramon Garcia, M.D. (1922-2004), reproductive medicine visionary". Journal of Experimental & Clinical Assisted Reproduction. 2 (1): 2. doi:10.1186/1743-1050-2-2. PMC 548289. PMID 15673473.
191. Junod SW, Marks L (April 2002). "Women's trials: the approval of the first oral contraceptive pill in the United States and Great Britain". Journal of the History of Medicine and Allied Sciences. 57 (2): 117–60. doi:10.1093/jhmas/57.2.117. PMID 11995593. S2CID 36533080.
192. Tyler ET, Olson HJ (April 1959). "Fertility promoting and inhibiting effects of new steroid hormonal substances". Journal of the American Medical Association. 169 (16): 1843–54. doi:10.1001/jama.1959.03000330015003. PMID 13640942.
193. Winter IC (1957). "Summary". Proceedings of a Symposium on 19-Nor Progestational Steroids. Chicago: Searle Research Laboratories. pp. 120–122. OCLC 935295.
194. Marks L (2001). Sexual Chemistry: A History of the Contraceptive Pill. New Haven: Yale University Press. ISBN 978-0-300-08943-1.
195. Winter IC (May 1970). "Industrial pressure and the population problem--the FDA and the pill". JAMA. 212 (6): 1067–8. doi:10.1001/jama.212.6.1067. PMID 5467404.
196. Watkins ES (1998). On the Pill: A Social History of Oral Contraceptives, 1950–1970. Baltimore: Johns Hopkins University Press. ISBN 978-0-8018-5876-5.
197. Winter IC (March 1965). "The incidence of thromboembolism in Enovid users". Metabolism. 14 (Supplement): SUPPL:422–8. doi:10.1016/0026-0495(65)90029-6. PMID 14261427.
198. Jordan WM, Anand JK (November 18, 1961). "Pulmonary embolism". Lancet. 278 (7212): 1146–1147. doi:10.1016/S0140-6736(61)91061-3.
199. Seaman B (1969). The Doctors' Case Against the Pill. New York: P. H. Wyden. ISBN 978-0-385-14575-6.
200. FDA (June 11, 1970). "Statement of policy concerning oral contraceptive labeling directed to users". Federal Register. 35 (113): 9001–9003.
201. FDA (January 31, 1978). "Oral contraceptives; requirement for labeling directed to the patient". Federal Register. 43 (21): 4313–4334.
202. FDA (May 25, 1989). "Oral contraceptives; patient package insert requirement". Federal Register. 54 (100): 22585–22588.
203. "Prescriptive Authority for Pharmacists: Oral Contraceptives". Pharmacy Times. November 2018 Cough, Cold, & Flu. 84 (11). 19 November 2018. Retrieved 2019-08-02.
204. "Pharmacist Prescribing for Hormonal Contraceptive Medications". NASPA. Retrieved 2019-08-02.
205. "Pharmacists Authorized to Prescribe Birth Control in More States". NASPA. 2017-05-04. Retrieved 2019-08-02.
206. . Archived from the original on April 15, 2008. Retrieved 2007-12-06.{{cite web}}: CS1 maint: bot: original URL status unknown (link)
207. Van den Broeck K (5 March 2010). "Gynaecoloog Ferdinand Peeters: De vergeten stiefvader van de pil" [Gynecologist Ferdinand Peeters: The forgotten stepfather of the pil]. Knack (in Dutch). pp. 6–13. Extra #4.
208. Hope A (May 24, 2010). "The little pill that could". Flanders Today.
209. Mears E (November 1961). "Clinical trials of oral contraceptives". British Medical Journal. 2 (5261): 1179–83. doi:10.1136/bmj.2.5261.1179. PMC 1970272. PMID 14471934.
210. Eckstein P, Waterhouse JA, Bond GM, Mills WG, Sandilands DM, Shotton DM (November 1961). "The Birmingham oral contraceptive trial". British Medical Journal. 2 (5261): 1172–9. doi:10.1136/bmj.2.5261.1172. PMC 1970253. PMID 13889122.
211. Pullen D (October 1962). ""Conovid-E" as an oral contraceptive". British Medical Journal. 2 (5311): 1016–9. doi:10.1136/bmj.2.5311.1016. PMC 1926317. PMID 13972503.
212. Mears E, Grant EC (July 1962). ""Anovlar" as an oral contraceptive". British Medical Journal. 2 (5297): 75–9. doi:10.1136/bmj.2.5297.75. PMC 1925289. PMID 14471933.
213. "Annotations". British Medical Journal. 2 (5258): 1007–9. October 1961. doi:10.1136/bmj.2.3490.1009. PMC 1970146. PMID 20789252.
     "Medical News". BMJ. 2 (5258): 1032–1034. 1961. doi:10.1136/bmj.2.5258.1032. S2CID 51696624.
214. Chàvez L, Takahashi A, Yoshimoto T, Su CC, Sugawara T, Fujii Y (March 1990). "Morphological changes in normal canine basilar arteries after transluminal angioplasty". Neurological Research. 12 (1): 12–6. doi:10.1136/bmj.2.5266.1584. PMID 1970619. S2CID 8849008.
215. . Time. Vol. 78, no. 24. December 15, 1961. p. 55. Archived from the original on February 5, 2008.
216. Dourlen Rollier AV (October 1972). "[Contraception: yes, but...]". Fertilité, Orthogénie. 4 (4): 185–8. PMID 12306278.
217. "The Aids Generation: the pill takes priority?". Science Actualities. 2000. Retrieved 2006-09-07.
218. (Press release). Stanford University News Service. 1996-02-14. Archived from the original on 2007-01-06. Retrieved 2006-08-23.
219. Wudunn S (27 April 1999). "Japan's Tale of Two Pills: Viagra and Birth Control". The New York Times.
220. Efron S (1999-06-03). "Japan OKs Birth Control Pill After Decades of Delay". Los Angeles Times. Retrieved 2022-08-31.
221. Efron S (3 June 1999). "Japan OKs Birth Control Pill After Decades of Delay". Los Angeles Times.
222. Hayashi A (2004-08-20). "Japanese Women Shun The Pill". CBS News. Retrieved 2006-06-12.
223. . Time. April 7, 1967. Archived from the original on February 19, 2005. Retrieved June 16, 2020.
224. Westhoff C (15 December 2015). "How Obamacare Explains the Rising Popularity of IUDs". Public Health Now at Columbia University. Retrieved 2020-06-17.
225. (PDF). Archived from the original (PDF) on 2021-12-09. Retrieved 2018-10-20.
226. Goldin C, Katz L (2002). "The Power of the Pill: Oral Contraceptives and Women's Career and Marriage Decisions" (PDF). Journal of Political Economy. 110 (4): 730–770. CiteSeerX 10.1.1.473.6514. doi:10.1086/340778. S2CID 221286686.
227. "The Pill". Equality Archive. 2017-03-01. Retrieved 2017-03-09.
228. Weigel G (2002). The Courage to Be Catholic: Crisis, Reform, and the Renewal of the Church. Basic Books.
229. "Pillenverbot bleibt Streitfrage zwischen den Konfessionen". Focus Online.
230. "1970 Year in Review". UPI.
231. Winnick C (1968). "The Beige Epoch: Depolarization of Sex Roles in America". The Annals of the American Academy of Political and Social Science. 376: 18–24. doi:10.1177/000271626837600103. JSTOR 1037799. S2CID 145158114.
232. "Richard Brautigan: The Pill versus The Springhill Mine Disaster". www.brautigan.net. Retrieved 2017-12-01.
233. . gender.stanford.edu. Archived from the original on 2017-12-12. Retrieved 2017-12-01.
234. Williams RJ, Johnson AC, Smith JJ, Kanda R (May 2003). "Steroid estrogens profiles along river stretches arising from sewage treatment works discharges". Environmental Science & Technology. 37 (9): 1744–50. Bibcode:2003EnST...37.1744W. doi:10.1021/es0202107. PMID 12775044.
235. "Not Quite Worry-Free". Environment. 45 (1): 6–7. Jan–Feb 2003. doi:10.1080/00139150309604545. S2CID 218496430.
236. Batt S (Spring 2005). (PDF). Herizons. 18 (4): 12–3. Archived from the original (PDF) on 2012-03-15. Retrieved 2011-12-04.
237. Zeilinger J, Steger-Hartmann T, Maser E, Goller S, Vonk R, Länge R (December 2009). "Effects of synthetic gestagens on fish reproduction". Environmental Toxicology and Chemistry. 28 (12): 2663–70. doi:10.1897/08-485.1. PMID 19469587.
238. Johnson AC, Williams RJ, Simpson P, Kanda R (May 2007). "What difference might sewage treatment performance make to endocrine disruption in rivers?". Environmental Pollution. 147 (1): 194–202. doi:10.1016/j.envpol.2006.08.032. PMID 17030080.
239. Potts M, Marsh L (February 2010). (PDF). OurPlanet.com. Archived from the original (PDF) on 4 March 2016. Retrieved 22 June 2015.
240. Cafaro P. "Alternative Climate Wedges – Population Wedge". Philip Cafaro. Retrieved 22 June 2015.
241. Wire T (10 September 2009). "Contraception is 'greenest' technology". London School of Economics. Retrieved 22 June 2015.

Further reading

• Black A, Guilbert E, Costescu D, Dunn S, Fisher W, Kives S, et al. (April 2017). "No. 329-Canadian Contraception Consensus Part 4 of 4 Chapter 9: Combined Hormonal Contraception". Journal of Obstetrics and Gynaecology Canada. 39 (4): 229–268.e5. doi:10.1016/j.jogc.2016.10.005. PMID 28413042.

External links

• The Birth Control Pill—CBC Digital Archives
• —slide show by Life magazine